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“No digáis que, agotado su tesoro, 
de asuntos falta, enmudeció la lira; 
podrá no haber poetas; pero siempre 
habrá poesía. 
… 
Mientras la ciencia a descubrir no alcance 
las fuentes de la vida, 
y en el mar o en el cielo haya un abismo 
que al cálculo resista, 
mientras la humanidad siempre avanzando 
no sepa a dó camina, 
mientras haya un misterio para el hombre, 
¡habrá poesía!” 
 






POPULAR SCIENCE SUMMARY OF THE THESIS 
 
According to the World Health Organization (WHO), cancer remains the second leading cause 
of deaths around the world. They estimate that about one in three people will develop cancer 
during their lives. Despite our best efforts to develop better treatments, our current ones still 
cause great discomfort and suffering to the patients and their families. 
Approximately 90% of all cancer patients receive radio- and/or chemotherapy, which have 
considerable side effects. These harmful effects are usually caused by the treatment not being 
able to tell the difference between cancer and normal cells, which results in healthy tissue being 
affected as well. This highlights the need for more precise therapies with fewer side effects. 
Previous studies show that certain proteins, such as PFKFB3 and MTHFD2, are commonly 
overproduced in cancer cells. While these proteins are normally involved in breaking down 
nutrients like sugars and folic acid to produce energy and cell components, we have discovered 
that in cancer they can have other functions like protecting the cell’s DNA, i.e., the master code 
with instructions to how the cells should work and how to make new cells. 
Under normal circumstances, MTHFD2 is almost non-existent in adult healthy tissue; it is 
present only in embryos before cells mature into specialized organs. In embryos, MTHFD2 is 
important for fast growth because it provides the building blocks for all the DNA being 
assembled in the new cells. These DNA building blocks, called nucleotides, are part of the 
reason pregnant women are encouraged to take more folic acid – the embryo’s MTHFD2 
requires folic acid to make nucleotides. Cancer cells, like embryonic cells, divide extremely 
fast and find it convenient to reactivate MTHFD2 in order to make more DNA building blocks 
to support their fast growth.  
In the case of PFKFB3, we found that when DNA is damaged by radiotherapy for example, 
PFKFB3 helps recruit the repair proteins needed to make new DNA building blocks and fix 
the damage. If left unrepaired, the DNA damage would cause cell death, a mechanism put in 
place to prevent corrupted DNA code from being passed on to new cells. Therefore, tumors 
benefit from overproducing PFKFB3 to avoid death when their DNA is damaged. 
Our group has collaborated with the pharmaceutical company Kancera to test their recently 
developed anti-PFKFB3 drug, while we have generated several drugs of our own that inhibit 
MTHFD2. These drugs kill the cancer cells which rely on PFKFB3 or MTHFD2, while largely 
sparing the healthy cells which do not have as much of these proteins. Our hope is that we can 
use these new drugs to treat many types of cancer more precisely, alone or in combination with 
radiotherapy and other drugs, to reduce the side effects for patients and even sensitize cancers 




Altered tumor metabolism has been described as early as the 1920s, but it was only in recent 
decades that proteomic and metabolomic studies revealed that the ways in which tumors rewire 
their nutrient and energy pathways are more diverse and have more implications for treatment 
outcome than previously thought. There is now a great interest in characterizing promising 
metabolic targets and identifying novel ways by which to exploit them for cancer treatment. 
This thesis work is part of an ongoing effort to elucidate the molecular mechanisms behind 
metabolic cancer targets specifically at the interface of genome stability, their role in the 
pathogenesis of different tumor types and genetic contexts, and their suitability as drug targets 
for clinically relevant treatment strategies.  
In Paper I, we present a new role for the glycolysis enzyme 6-phosphofructo 2-kinase/fructose 
2,6-bisphosphatase 3 (PFKFB3) in homologous recombination (HR). We used gene silencing 
and pharmacological inhibitors to investigate the role of PFKFB3 in the response to DNA 
damage induced by ionizing radiation (IR). We found that PFKFB3 promotes the recruitment 
of DNA repair factors and supplies nucleotides for DNA synthesis through its interaction with 
ribonucleotide reductase (RNR). We also validated the antitumor preclinical potential of 
PFKFB3 inhibitor KAN0438757 and showed it specifically sensitized cancer cells to IR. 
In Paper II, we solve the first crystal structure of human one-carbon metabolism enzyme 
methylenetetrahydrofolate dehydrogenase 2, methenyltetrahydrofolate cyclohydrolase 
(MTHFD2) in complex with its cofactors and a weak inhibitor, LY345899. We developed 
biochemical activity and target engagement assays to evaluate the binding and inhibition of 
MTHFD2 by LY345899 in cancer cell models. With the newfound structural insights to 
determine key residues important for substrate and cofactor binding, we were able to undertake 
a structure-based drug discovery program targeting MTHFD2 detailed in Paper III.  
Paper III expands on the groundwork laid out in Paper II to develop first-in-class, highly 
potent and cell active inhibitors of MTHFD2 (MTHFD2i). Again, using gene silencing 
techniques, we identified a novel role for MTHFD2 in genome maintenance, which we 
confirmed with our small molecule inhibitors. We show that MTHFD2i induce replication 
stress and apoptosis selectively in transformed cells as a result of impaired de novo thymidylate 
synthesis and genomic uracil misincorporation. We established an in vivo model of acute 
myeloid leukemia (AML) and showed that MTHFD2i significantly prolonged survival and 
outperformed the standard of care compound cytarabine (AraC), providing proof-of-concept 
for the translational potential of MTHFD2i as anticancer drugs.   
In Paper IV, we further elaborate on the role of MTHFD2 in genome maintenance in response 
to DNA damage. We found that MTHFD2 accumulates and associates to chromatin upon DNA 
double strand breaks (DSBs) and promotes DNA repair through HR. Loss of MTHFD2 
 
 
significantly impairs HR activity, with MTHFD2i specifically sensitizing cancer cells to PARP 
inhibitors in vitro and delaying tumor growth when combined with a PARP inhibitor in vivo.  
Taken together, these studies showcase these two metabolic enzymes, PFKFB3 and MTHFD2, 
in a new light as novel DNA damage response (DDR) targets. Our findings provide compelling 
evidence to propose the intersection of cancer metabolism and genome stability as an untapped 
source of novel anticancer targets warranting more mechanistic and drug development efforts.  
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LIST OF ABBREVIATIONS 
 
Genes and proteins 
 
53BP1  Tumor protein p53 binding protein 1 
6PGD  6-phosphogluconate dehydrogenase 
ACLY  ATP-citrate lyase 
AKT  Protein kinase B (tyrosine kinase) 
AMT  Aminomethyltransferase 
ATM  Ataxia-telangiectasia mutated kinase 
ATF4  Activating transcription factor 4 
ATR  Ataxia- and Rad3-related kinase 
BRCA1  Breast cancer type 1 susceptibility protein 
BRCA2  Breast cancer type 2 susceptibility protein 
CAD Carbamoyl-phosphate synthetase 2-aspartate transcarbamoylase-
dihydroorotase 
CDA  Cytidine deaminase 
CDK1  Cyclin-dependent kinase 1  
CDK4  Cyclin-dependent kinase 4 
CHK1  Checkpoint kinase 1 
CtIP  CTBP-interacting protein; Rb binding protein 8 (endonuclease) 
DHFR  Dihydrofolate reductase 
DHODH  Dihydroorotate dehydrogenase 
DNA-PKcs  DNA-dependent protein kinase catalytic subunit 
dUTPase   Deoxyuridine triphosphate pyrophosphatase  
EXO1  Exonuclease 1 
FH  Fumarate hydratase 
FOLH1  Folate hydrolase 1; PSMA1  
FPGS  Folate polyglutamate synthetase 
G6PD  Glucose-6-phosphate dehydrogenase 
GARFT  Glycinamide ribonucleotide formyltransferase 
GFP  Green fluorescent protein 
GGH  Gamma-glutamyl hydrolase 
GS  Glutamine synthetase 
HER2  Human epidermal growth factor receptor 2 
HIF-1α  Hypoxia-inducible factor 1α 
HK  Hexokinase 
IDH  Isocitrate dehydrogenase 
IMPDH  Inosine-5’-monophosphate dehydrogenase 
KAP1  KRAB-associated protein-1; TRIM28; TIF1β 
KRAS  Kirsten rat sarcoma oncogene homolog (GTPase) 
Ku70  Thyroid autoantigen 70 kDa; XRCC6 
Ku86  Thyroid autoantigen 80 kDa; XRCC5 
MDC1  Mediator of DNA damage checkpoint 1 
MRE11  Meiotic recombination 11 
MRN  MRE11-RAD50-NBS1 complex 
MTHFD1  Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and 
formyltetrahydrofolate synthetase 1 
MTHFD1L  Methylenetetrahydrofolate dehydrogenase 1 like 




MTHFD2L  Methylenetetrahydrofolate dehydrogenase 2 like 
MTHFR  Methylene tetrahydrofolate reductase 
mTOR  Mammalian target of rapamycin 
MYC  Myelocytomatosis homolog 
NBS1  Nijmegen breakage syndrome 1 
NDPK  Nucleoside diphosphate kinase 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NRF2  Nuclear factor, erythroid 2 like 2 
P27  Cyclin-Dependent Kinase Inhibitor 1B; Kip1 
P53  Tumor protein p53; Tp53 
PAICS Phosphoribosylaminoimidazole carboxylase and phosphoribosyl-
aminoimidazolesuccinocarboxamide synthase 
PARP1  Poly(ADP-ribose) polymerase 1 
PCFT  Proton-coupled folate transporter 
PFK-1  6-phosphofructo-1-kinase 
PFKFB3  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
PGAM1  Phosphoglycerate mutase 1 
PHGDH  Phosphoglycerate dehydrogenase 
PI3K  Phosphoinositide-3-kinase 
PKM2  Pyruvate kinase M2 
PPAT  Phosphoribosyl pyrophosphate amidotransferase 
PRPS2  Phosphoribosyl pyrophosphate synthetase 2 
PTEN  Phosphatase and tensin homolog 
RAD50  RAD50 double strand break repair protein 
RAD51  RAD51 recombinase, RecA homolog 
RAS  Rat sarcoma oncogene homolog 
RFC  Reduced folate transporter 
RNR  Ribonucleotide reductase 
RPA  Replication protein A 
RPA32  Replication protein A2; RPA2 
RRM2  Ribonucleotide reductase regulatory subunit M2 
SDH  Succinate dehydrogenase 
SHMT1  Serine hydroxymethyltransferase 1 
SHMT2  Serine hydroxymethyltransferase 2 
SOD1  Superoxide dismutase 1 
SUMO  Small ubiquitin-like modifier 
TMPK  2’-deoxythymidine-5’-monophosphate kinase 
TS  Thymidylate synthase; TYMS 
UNG  Uracil DNA glycosylase 
WEE1  WEE1 G2 checkpoint kinase 
γH2AX  Histone H2A, variant X, phosphorylated at Ser139 
 
 
Metabolites, drugs and compounds 
 
2-DG  2-deoxyglucose 
2-PG  2-phosphoglycerate 
3-PG  3-phosphoglycerate 
5-FU  5-fluorouracil 
5-FUdR   5-fluorodeoxyuridine 
5-meTHF  5-methyl tetrahydrofolate 
5,10-meTHF  5,10-methylene tetrahydrofolate; CH2-THF 
Acetyl-CoA  Acetyl coenzyme A 
AMP  Adenosine monophosphate 
AraC  Cytosine arabinoside; cytarabine 
ATP  Adenosine triphosphate 
ATRA  All-trans retinoic acid 
BrdU  5-bromo-2’-deoxyuridine 
CldU  5-chloro-2'-deoxyuridine 
CO2  Carbon dioxide 
dNTP  Deoxyribonucleotide triphosphate 
dCTP  2’-deoxycytidine-5’-triphosphate 
dTMP  2’-deoxythymidine-5’-monophosphate 
dTTP  2’-deoxythymidine-5’-triphosphate 
dUMP  2’-deoxyuridine-5’-monophosphate 
dUTP  2’-deoxyuridine-5’-triphosphate 
DMSO  Dimethyl sulfoxide 
EdU  5-ethynyl-2′-deoxyuridine 
F1,6BP  Fructose-1,6-bisphosphate 
F2,6BP  Fructose-2,6-bisphosphate 
F6P  Fructose-6-phosphate 
GMP  Guanosine monophosphate 
GTP  Guanosine triphosphate 
HU  Hydroxyurea 
IdU  5-iodo-2'-deoxyuridine 
IMP  Inosine 5'-monophosphate 
NAD+  Nicotinamide adenine dinucleotide 
NADH  Reduced nicotinamide adenine dinucleotide 
NADP+  Nicotinamide adenine dinucleotide phosphate 
NADPH  Reduced nicotinamide adenine dinucleotide phosphate 
OMP  Orotate monophosphate 
PRPP  Phosphoribosyl pyrophosphate 
SAM  S-adenosylmethionine 
THF  Tetrahydrofolate 





ADME  Absorption, distribution, metabolism, and excretion 
ALL  Acute lymphoblastic leukemia 
AML  Acute myeloid leukemia 
CETSA  Cellular thermal shift assay 
CRISPR/Cas9 Clustered regularly interspaced short palindromic repeats/ 
CRISPR-associated protein 9 
DARTS  Drug affinity responsive target stability 
DDR  DNA damage response 
DNA  Deoxyribonucleic acid 
DR-GFP  Direct repeat green fluorescent protein 
DSB  DNA double strand break 
DSF  Differential scanning fluorimetry 
ETC  Electron transport chain 
HR  Homologous recombination 
IR  Ionizing radiation 
 
 
ITDRF  Isothermal dose-response fingerprint 
mRNA  Messenger ribonucleic acid 
NHEJ  Non-homologous end joining 
PCR  Polymerase chain reaction 
PPP  Pentose phosphate pathway 
RNA  Ribonucleic acid 
RNAi  Interfering ribonucleic acid 
ROS  Reactive oxygen species 
SAR  Structure-activity relationship 
siRNA  Small interfering ribonucleic acid  
SPR  Surface plasmon resonance 
SSB  DNA single strand break  
ssDNA  Single strand DNA 
TCA cycle  Tricarboxylic acid cycle; Krebs cycle   
Tm  Melting temperature 
TSA  Thermal shift assay 
UV  Ultraviolet 







1.1 METABOLIC REPROGRAMMING IN CANCER 
 
1.1.1 Oncogene-driven remodeling of metabolic and energetic pathways 
 
The relationship between cellular energy metabolism and oncogenesis was first described 
almost 100 years ago in the 1920s by Otto Warburg and his colleagues (1). They discovered 
that tumor cells shift their glucose metabolism to favor increased rates of anaerobic glycolysis 
and lactose fermentation independently of oxygen availability, a phenomenon known today as 
the Warburg effect (1,2). At the time, many misinterpreted these observations to mean that 
cancer was caused by defective mitochondrial respiration and metabolism, including Warburg 
himself (3). This initial lack of understanding resulted in cancer metabolism being heavily 
criticized and largely dismissed for the greater part of the 20th century (2), and further 
overlooked with the rise of molecular oncology and cancer genetics in the late 1980s (4). The 
discovery of the first oncogenes and tumor suppressors held the promise of exposing the root 
cause of all neoplastic transformation, redefining the paradigm of cancer research for decades 
to follow; a view which held genetic alterations as the sole key driving force for oncogenesis, 
and relegated metabolic rewiring to a mere side-effect (5,6).     
Today we understand that, despite increased glycolysis, mitochondrial metabolism is rather 
preserved by cancer cells and even indispensable for their growth and survival (7,8). The effects 
observed by Warburg are the likely result of deregulated glycolysis via hypoxia-inducible 
factor 1α (HIF-1α) modulation rather than defective mitochondria (9–12), effects which can 
exist to various degrees and concurrently with mitochondrial respiration in many cancer types 
(13,14). Over the past two decades, the development of highly performant biophysical and 
computational methods giving rise to the proteomics and metabolomics age have greatly 
rekindled the interest for studying the deregulation of metabolic pathways in cancer, with 
extensive data highlighting its importance for cancer development and progression (15–21). 
Nowadays considered a hallmark of cancer (22), the reprogramming of energy metabolism 
represents an important trait acquired by cancer cells to redirect cellular resources, including 
building blocks and energy supplies, to support the elevated levels of biosynthesis that 
accompany increased cell proliferation (23). 
The connection between cancer genetic alterations and metabolic reprogramming remains a 
highly intricate one, with most oncogenes and tumor suppressors, including p53, MYC, RAS 
and AKT, having direct effects over major metabolic pathways, and vice-versa (Figure 1)  (24–
26). Most of these genetic and metabolic alterations induce deregulation of cell growth and 
division, providing the basis for anticancer chemotherapy. However, normal cells in the bone 
marrow and in the intestinal crypts, as well as other tissues, also undergo rapid proliferation, 
often at higher rates than cancer cells (27). This lack of cancer specificity has long represented 
the greatest limitation of chemotherapy, with severe myeloid and gastrointestinal toxicity often 
 
8 
being dose-limiting for these drugs (28). Since the rediscovery of tumor metabolism as a 
validated source of anticancer strategies, extraordinary efforts to uncover and target cancer-
specific metabolic features have resulted in the approval and clinical success of new 











Figure 1. Oncogenic and tumor suppressor signaling regulating cancer metabolism. Oncogenes and tumor 
suppressors are shown in purple, key metabolic pathways are shown in pink, with the main biosynthetic areas 
labeled in blue. Reprinted from DeBerardinis & Chandel, 2016 (33), with permission from the American 
Association for the Advancement of Science (AAAS). 
 
1.1.2 Metabolic alterations as a source of novel oncotargets 
 
The link between cancer and altered cellular metabolism has been further validated by the 
discovery of cancer-associated mutations in metabolic enzyme genes (34). Thanks to advances 
in mass spectrometry and nuclear magnetic resonance methods used for the high-resolution 
profiling of low-weight metabolites (35–38), some of these metabolic gene mutations have 
been found to result in abnormal accumulation of metabolites at the root of cellular process 
deregulation and malignant transformation in cancer cells (25,34,39,40).   
The best-known examples of metabolic oncotargets were identified using metabolic profiling 
of tumor cells which revealed abnormal accumulation of tricarboxylic acid (TCA) cycle 
intermediates as a result of loss- and gain-of-function mutations in genes encoding the 
metabolic enzymes succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate 
dehydrogenase (IDH) (41–43). Deregulation of mitochondrial function characterized by TCA 
cycle defects has been associated with overproduction of reactive oxygen species (ROS), which 
is known to influence oncogenic signaling and tumor progression through the oxidative damage 
of proteins and nucleotides (44,45). Therefore, the metabolic pathways that lead to the 
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production of oncometabolites and the downstream signaling pathways that are activated by 
oncometabolites represent potential therapeutic targets, some of which are successfully 
exploited in the clinic today (Figure 2) (30,46,47). 
Modern metabolomic approaches together with metabolic flux models using isotope tracers 
can provide direct pathophysiological insights into tumor metabolism and serve as an excellent 
tool for biomarker discovery. For example, Jain et al. analyzed the metabolic profiles of the 
NCI-60 panel of cancer cell lines and, using a data-driven approach, identified glycine 
consumption as a key metabolic driver of rapid proliferation in cancer cells (48). They found 
MTHFD2 expression to be among the topmost correlated with proliferation rates, thus 























Figure 2. Overview of current therapeutic targets exploiting cancer metabolism. Cancer metabolism has been 
the target of cancer therapy since the early days of chemotherapy, with antifolates among the first targeted 
treatments. Our understanding of cancer metabolism has advanced significantly in recent years and is being used 
for the development of novel targeted therapies. Reprinted from Vazquez et al. 2016 (49). Copyright © 2016. 
Published by The Company of Biologists Ltd. 
 
1.1.3 Glycolysis and PFKFB3 
 
As the most abundant and ubiquitous source of energy, glucose and its metabolism are key 
determinants in the growth and expansion of dividing cells, and in particular tumor cells. Most 
of the glucose consumed by cells is normally catabolized through glycolysis to pyruvate, which 
fuels the TCA cycle and the electron transport chain (ETC) in aerobic cells (Figure 3). Glucose 
catabolism coupled to oxidative phosphorylation has a high energy yield in the form of ATP. 
Cancer cells, paradoxically, convert much of the pyruvate into lactate, which is then excreted 
to the extracellular medium, a phenotype known as the Warburg effect (25). Several glycolytic 
genes are usually overexpressed in tumors and give place to this effect (50). Even though 
catabolism of glucose into lactate has an extremely low energy yield, the percentage of ATP 
generated from glycolysis can surpass that produced by oxidative phosphorylation if the 
glycolytic flux is high enough (51–53). Furthermore, glucose metabolism provides 
intermediates that are needed for biosynthetic pathways, such as ribose sugars for nucleotide 
synthesis, acetyl-CoA for lipid production, non-essential amino acids and NADPH. Therefore, 
and as long as the rate is high enough, the glycolytic phenotype can fuel many of the cancer 








Figure 3. Differences in ATP output between oxidative phosphorylation, anaerobic and aerobic glycolysis. 
In aerobic conditions, differentiated tissues metabolize glucose to pyruvate via glycolysis and then shuttle most of 
it to the mitochondria for oxidative phosphorylation. Since oxygen is required as the final electron acceptor in the 
ETC, oxygen is indispensable for this process. In anaerobic conditions, cells can redirect the pyruvate generated 
by glycolysis into lactate production (anaerobic glycolysis). This allows glycolysis to continue (by cycling NADH 
back to NAD+) but results in minimal ATP production. Cancer cells tend to convert most glucose to lactate 
independent of oxygen availability (aerobic glycolysis). Mitochondria remain functional and oxidative 
phosphorylation can continue to varying extents in both cancer and normal proliferating cells. However, aerobic 
glycolysis remains significantly less efficient at generating ATP than oxidative phosphorylation. Reprinted from 
Vander Heiden et al., 2009 (25), with permission from AAAS. 
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Glycolysis is tightly regulated by various mechanisms acting at different levels of the pathway 
(Figure 4). The first committed rate-limiting step of glycolysis involves the conversion of 
fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6BP) by 6-phosphofructo-1-
kinase (PFK-1), and represents a key regulation point in the pathway (54). Fructose 2,6-
bisphosphate (F2,6BP) is a potent activator of PFK-1 (55), whose intracellular concentration is 
regulated by the family of bifunctional enzymes PFK-2/FBPase (PFKFB) (56,57). The four 
isozymes (PFKFB1-4), while sharing high sequence homology in their core domains, display 
quite different profiles when it comes to kinase-to-phosphatase activity ratios, tissue 
expression, and response to various signaling cascades (58,59). Among these isozymes, 
PFKFB3 has by far the highest kinase-to-phosphatase ratio (~740:1), which strongly promotes 
high glycolytic rates (60). Consequently, PFKFB3 has been shown to contribute to the Warburg 
effect and the hypoxia response (61–67), and therefore represents a promising target for 















Figure 4. Overview of the main glycolysis steps in cancer cells. Catalytic enzymes for each step are shown in 
yellow or purple ovals. The three main modulating enzymes of the pathway are shown in bold. HK, hexokinase; 
G6P, glucose-6-phosphate; PPP, pentose phosphate pathway; GPI, glucose-6-phosphate isomerase; F6P, fructose-
6-phosphate; F2,6BP, fructose-2,6-bisphosphate; PFK-1, phosphofructokinase 1; F1,6BP, fructose-1,6-
bisphosphate; PEP, phosphoenolpyruvate; PK, pyruvate kinase; LDHA, lactate dehydrogenase; TCA, 
tricarboxylic acid. Reprinted from Wang et al., 2020 (68), with permission from Elsevier. Copyright © 2020 
Elsevier Inc. All rights reserved. 
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PFKFB3 consists of two homodimeric subunits, each consisting of two functional domains 
(56,58,59). The C-terminal domain contains the bisphosphatase activity of the enzyme (69–
71), while the N-terminal domain is responsible for its kinase activity (70). The relative lack of 
PFKFB3 phosphatase activity can be explained by a conformational rearrangement of C-
terminal residues 440-446 which has not been observed in the other PFKFB isoforms (72). 
Several small molecule inhibitors of PFKFB3 have been developed, including 3PO, PFK15, 
PFK-158, with the latter having shown promising anticancer and immunomodulatory effects 
in clinical trials (73–76). However, the complex inhibitory mechanisms of these compounds 
and how they relate to their effect on different PFKFB3-mediated and -independent processes 
are still under investigation. 
PFKFB3 protein expression is found in all tissues, but is specifically expressed at higher levels 
in adipose and brain tissue, as well as in transformed cells (77,78). PFKFB3 is frequently 
overexpressed in colon cancer, breast cancer, hepatocellular carcinoma, and glioma (79–82). 
Its expression is upregulated during the S phase of the cell cycle, and in response to hypoxia, 
inflammation and hormone receptor signaling (64,77,83,84). In addition to transcriptional 
control of PFKFB3 expression, various post-translational modifications of PFKFB3, e.g., 
phosphorylation, ROS-dependent S-glutathionylation, polyubiquitination, methylation and 
acetylation, can regulate its activity, stability and subcellular localization, allowing cancer cells 
to make rapid adaptive changes in response to metabolic stress (80,85–90). 
In particular, PFKFB3 activity has been described as a direct link between oncogenic signaling 
and regulation of glucose metabolism in various tumor types (91,92). Upon mitotic arrest, 
prolonged energy deprivation activates AMP-activated protein kinase (AMPK), which 
phosphorylates PFKFB3 to promote glycolysis and evade cell death (93). In glioblastoma, 
inhibition of RAS signaling downregulates HIF-1α and thereby the expression of PFKFB3, 
hampering glycolysis and causing cell death (94). In breast cancer, constitutive HER2 signaling 
promotes PFKFB3 expression and increases glycolysis (95). In myeloid leukemias, PFKFB3 
is transcriptionally repressed by myeloid translocation gene 16 (MTG16), thereby promoting 
mitochondrial respiration and inhibiting cell proliferation (96), while expression of PFKFB3 is 
activated by transcription factor PU.1 in chronic myeloid leukemia cells resistant to tyrosine 
kinase inhibitors (97). Moreover, loss of tumor suppressors such as p53 or PTEN has also been 





Table 1. Overexpression of PFKFB3 in various cancer types 
Cancer type Study material Context Reference 
Breast cancer 
HMEC, MCF-10A, SKBR3,  
BT-474 
In vitro (95) 
HER2+ patient material In vitro (83) 
MCF-7, T47D In vitro (84) 
MCF-7, T47D, SUM159 In vitro (100) 
Breast cancer patient material, 
MDA-MB-231, MDA-MB-438, 
HUVEC 
In vitro (101) 
Melanoma 
451LU, WM983 In vitro (102) 
A375 
In vitro,  
in vivo 
(103) 
DB-1, SK-MEL-5 In vitro (104) 
Gastric cancer 
MKN45, AGS, BCG823, GES-1 
In vitro,  
in vivo 
(74) 
MKN45, NUGC3 In vitro (105) 
Colon 
adenocarcinoma 
Colorectal cancer patient material, 
SW480, SW1116 
In vitro,  
in vivo 
(106) 
HCT-116 In vitro (107) 
FFPE tissue material, SW620 In vitro (77) 
Panc1 In vitro (105) 
Panc1 In vitro (108) 
Ovarian cancer 
HeyA8, HeyA8MDR,  
OVCAR5, OV90 
In vitro (109) 
Lung cancer 
LLC1, H522 In vitro (110) 
H522, H1437, PC9, HCC827 In vitro (111) 
Bladder cancer T24, HUVEC In vitro (112) 
Glioblastoma 
and astrocytoma 
U87 In vitro (104) 
Glioblastoma patient material In vitro (113) 
Glioblastoma and astrocytoma 
patient material 
In vitro (82) 
Glioblastoma and astrocytoma 
patient material, U87 
In vitro (114) 
Head and neck 
carcinoma 
HNSCC patient material,  
Cal27, FaDu 
In vitro (115) 
Cervical cancer OV2008, C13 In vitro (109) 
Renal cancer ACHN In vitro (116) 
Thyroid cancer FFPE tissue material In vitro (77) 
Osteosarcoma 
U2OS In vitro (117) 
Osteosarcoma patient material, 
Saos-2 
In vitro (118) 
Acute myeloid 
leukemia 
THP-1, OCI-AML3 In vitro (119) 
Esophageal 
carcinoma 




In addition to its important role in glucose metabolism, PFKFB3 also carries out nuclear 
functions which support cancer proliferation independent from glycolysis (90). PFKFB3 
possesses a highly conserved nuclear localization motif allowing its relocation to the nucleus, 
where it has been shown to indirectly promote G1/S cell cycle progression and prevent 
apoptosis through its activity on CDK4 stabilization and CDK1-mediated degradation of p27 
(90,121–123). Furthermore, PFKFB3 has also been implicated in stimulating nucleotide 
synthesis for DNA repair in response to AKT and p53 signaling (81,124), as well as in HR 
repair of platinum-induced DNA damage (125), highlighting the existence of additional non-
glycolytic roles for PFKFB3 in cancer cells.     
To summarize, PFKFB3 plays a key role in the regulation of glycolysis, an important source 
of energy and biosynthetic intermediates on which cancer cells are particularly dependent on. 
The exploitability of this target for cancer therapy has been demonstrated by the development 
of potent PFKFB3 inhibitors with promising antitumor effects in clinical trials. Beyond its 
canonical role in glycolysis, nuclear functions of PFKFB3 may also be involved in promoting 
cancer development and require further investigation, to elucidate novel biological mechanisms 
and guide the development of additional therapeutic strategies using PFKFB3 inhibitors. 
 
1.1.4 One-carbon folate metabolism and MTHFD2 
 
Another consistently disrupted metabolic pathway in cancer is the folate cycle, which together 
with the methionine cycle constitute the one-carbon metabolic pathway (Figure 5) (48,126–
128). Altered folate metabolism in cancer cells was among the first metabolic pathways to be 
targeted for cancer therapy, with pioneering studies by Sidney Farber in the late 1940s 
demonstrating that the folate analog aminopterin was capable of inducing remission in children 
with acute lymphoblastic leukemia (ALL) (129,130). These observations gave rise to new 
folate analogs, or antifolates, such as methotrexate (a WHO-designated essential medicine 
(131)) and pemetrexed, drugs which inhibit one-carbon metabolism and are still widely used 
today in cancer treatment (132–136). The early success of antifolates resulted in the advance 
of other types of antimetabolites, molecules which mimic natural substrates and inhibit their 
target enzymes, often involved in nucleotide synthesis (137–139). Since the 1950s, the 
widespread adoption and continuous use of antimetabolites such as 6-mercaptopurine, 6-
thioguanine, 5-fluorouracil (5-FU), methotrexate, gemcitabine and cytarabine as standard-of-
care agents for different cancer types has dispelled any doubts that folate and nucleotide 















Figure 5. One-carbon metabolism is an integrator of nutrient status. One-carbon metabolism senses nutrient 
availabilities as cues to relocate resources into different biosynthetic pathways. It is composed of two modular 
units, the folate cycle and the methionine cycle. Depending on nutrient supply and demand, various outputs can 
be produced, including nucleotides, proteins, lipids, redox cofactors and substrates for methylation reactions. 
Reprinted by permission from Springer Nature: Nature Reviews Cancer, Locasale 2013 (128). Copyright © 2013, 
Nature Publishing Group, a division of Macmillan Publishers Limited. All rights reserved. 
 
Indeed, rapidly growing and dividing cancer cells require more than just ATP to sustain their 
survival – large amounts of nucleic acids, proteins, lipids and redox cofactors also need to be 
produced to build new cells (7,24,25,52,144–146). One-carbon metabolism comprises a 
complex network of metabolic reactions which rely heavily on folate compounds and redox 
cofactors to activate, carry, and process carbon units to make them available for the production 
of nucleotides, amino acids, and lipids (147–150). The folate cycle is coupled to the methionine 
cycle through the generation of 5-methyl-THF (5-meTHF), which is used for the remethylation 
of homocysteine to generate methionine (151). Methionine can in turn be used for protein 
synthesis, as well as production of S-adenosylmethionine (SAM), the main methyl carrier 
substrate required for post-translational modifications and epigenomic maintenance (152–155). 
SAM is also required for the synthesis of phosphatidylcholine, creatine and polyamines (156–
158). Together, the folate and methionine cycles are responsible for shunting carbon units into 
different biosynthetic pathways depending on specific cellular metabolic demands. 
The folate cycle is fueled by dietary folic acid, which is reduced by dihydrofolate reductase 
(DHFR) to the biologically active tetrahydrofolate (THF) and disseminated in the circulation 
as THF-monoglutamate (159). Cells uptake monoglutamylated folates via active transport 
using the reduced folate transporter (RFC) (160). Upon entering the cells, folates are further 
polyglutamylated by folate polyglutamate synthetase (FPGS), which increases their affinity to 
folate enzymes and reduces their affinity for RFC, thereby ensuring intracellular retention 
(161,162). In the cells, THF acts as an acceptor scaffold for one-carbon units, becoming 5,10-
methylene-THF (5,10-meTHF). Once loaded with carbon moieties, folates are unable to 
transfer across intracellular membranes – therefore, 5,10-meTHF must be generated in both the 
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cytosol and mitochondria independently (163). Serine and glycine are the main sources of one-
carbon units, with many other molecules being able to produce glycine upon cleavage and 
demethylation (150,164,165). The transfer of one-carbon units from serine to THF is mediated 
by serine hydroxymethyltransferases (SHMT1 and SHMT2, cytosolic and mitochondrial 
isozymes respectively), while glycine can be used by aminomethyltransferase (AMT) to 
produce 5,10-meTHF. Glucose-derived carbon units from glycolysis can also be redirected into 
the folate cycle via de novo serine production through the action of pyruvate kinase M2 
(PKM2) and phosphoglycerate dehydrogenase (PHGDH), among others (144,166–168). It has 
been known for many years that this pathway correlates with tumorigenesis, with PHGDH 











Figure 6. Folate-mediated one-carbon metabolism. In mammals, folate-mediated one-carbon metabolism is a 
highly compartmentalized and tightly regulated process. It possesses two main parallel branches, one 
mitochondrial and one cytosolic, each with its own set of specific isozymes and redox partners to convert between 
folate intermediaries. Interplay between the two modules is limited across the mitochondrial membrane. Adapted 
and reprinted from Ducker & Rabinowitz, 2016 (173), with permission from Elsevier. Copyright © 2016 Elsevier 
Inc. All rights reserved. 
 
The oxidation of 5,10-meTHF is a complex, multi-step process requiring three subsequent 
enzymatic activities: 5,10-methyl-THF dehydrogenase, 5,10-methenyl-THF cyclohydrolase, 
and 10-formyl-THF synthetase activities (Figure 6). This process is under additional 
spatiotemporal regulation, involving several different developmental and organelle-specific 
isozymes, each with different redox cofactor specificities. In the cytosol, interconversion 
between 5,10-meTHF and formate is carried out in its entirety by the trifunctional, NADP-
dependent MTHFD1. In the mitochondria, however, the bifunctional (dehydrogenase, 
cyclohydrolase) NAD-dependent MTHFD2L together with the monofunctional (synthetase) 
MTHFD1L are responsible for catalyzing these reactions (174). In undifferentiated tissue or 
 
 17 
during embryogenesis, the mitochondrial dehydrogenase and cyclohydrolase activities are 
carried out by MTHFD2 instead, as MTHFD2L is largely absent at early embryonic stages 
(175–178). Indeed, MTHFD2L seems to not have many crucial functions in highly proliferative 
tissues or cancer cells (179). 
Supply and demand of specific metabolic units in proliferating cells can determine the direction 
of flow and fate of one-carbon intermediaries, as most folate enzymes catalyze bidirectional 
reactions (180,181). For example, 5,10-meTHF can be used to support DNA synthesis by the 
action of thymidylate synthase (TS; TYMS), which converts deoxyuridine monophosphate 
(dUMP) to thymidine monophosphate (dTMP) (182). This is the target of standard-of-care 
anticancer agents such as 5-FU and raltitrexed (183–186). Alternatively, 5,10-meTHF can also 
be used for serine production by SHMT enzymes to satisfy high protein demands, or it can be 
fully oxidized to 10-formyl-THF for de novo purine synthesis (181,182,187,188). Moreover, 
folate cycle reactions can also produce redox cofactors, notably NADPH, which is important 
for maintenance of mitochondrial redox balance and has been implicated in cancer 
aggressiveness (189,190). Generally, mutations affecting genes involved in one-carbon 
metabolism often result in developmental defects in animals and humans, with most deletions 
being embryonic lethal, highlighting the crucial importance of this pathway for cell growth and 
proliferation (191–198).  
As one-carbon metabolism constitutes a key source of building blocks required to sustain 
proliferation and maintain redox balance, its upregulation in cancer cells is unsurprisingly 
common. In the last few years, several genomics and metabolomics studies have singled two 
main one-carbon metabolism nodes, de novo serine and mitochondrial folate pathways, among 
the most upregulated metabolic pathways in cancer (48,126–128,199). The increased 
expression of one-carbon enzymes seems to stem mainly from altered transcriptional regulation 
rather than genomic amplification. ATF4 and mTOR have recently been described to modulate 
transcriptional regulation of both de novo serine synthesis and mitochondrial one-carbon 
enzymes (200,201). MYC and RAS have also been shown to induce transcription of genes 
involved in mitochondrial function (127,202–205). In KRAS-mutated non-small cell lung 
cancer, expression of MTHFD2 was shown to correlate with response to pemetrexed (206). 
Among the metabolic genes commonly overexpressed in human tumors, MTHFD2 was 
identified as the most consistently upregulated metabolic enzyme across cancer types, as well 
as displaying the most cancer-specific expression profile (207). MTHFD2 overexpression 
levels have been associated with larger tumor size, increased metastasis and overall poor 
prognosis in breast cancer patients (208,209). Similarly, in acute myeloid leukemia (AML) in 
vivo models, loss of MTHFD2 alone was enough to impair cancer development and extend 
mouse survival (210). Furthermore, MTHFD2 has been shown to have nuclear localization and 
co-localize to DNA synthesis sites in cancer cells (211,212), not unlike other folate metabolism 
enzymes which rnrsupport dTMP production in the nucleus such as SHMT1, SHMT2α, 




Table 2. Antiproliferative effects of targeting MTHFD2 in different tumor types 
 
Cancer type Study material Method Context Reference 
Breast cancer 
MDA-MB-231 siRNA In vitro (208) 
Hs578T, MCF-7 shRNA In vitro (207) 
MCF-7 shRNA In vitro (218) 
MCF-7 shRNA In vitro (219) 




shRNA In vitro (207) 
HCT-116 CRISPR/Cas9 In vivo (181) 














HOP92, H226, EKVX, 
H460 
shRNA In vitro (207) 
Adenocarcinoma 





















HL-60, THP-1 siRNA In vitro (227) 
HL-60, THP-1 siRNA In vitro (228) 
Renal cancer 
A498 shRNA In vitro (207) 
786-O shRNA In vitro (229) 
786-O, CAK-1 shRNA In vivo (230) 
Glioblastoma 
U251, SNB-75, SF295  shRNA In vitro (207) 




Neuroblastoma SK-N-DZ shRNA In vitro (232) 
Ovarian cancer OVCAR8 shRNA In vitro (207) 
Melanoma LOX IMVI shRNA In vitro (207) 
Liver cancer HepG2, Huh7 siRNA In vitro (233) 
 
Altogether, MTHFD2 has been extensively validated as a promising anticancer target given its 
highly cancer-selective profile, the widespread expression of redundant MTHFD2L in normal 
tissue, and its function in supporting nucleotide synthesis in cancer. Toxicity and side effects 
of current antimetabolites could potentially be curbed by favoring MTHFD2 inhibition instead, 




1.2 DEREGULATION OF NUCLEOTIDE POOLS AND GENOME INSTABILITY  
 
1.2.1 Nucleotide synthesis pathways 
 
The maintenance of genomic integrity is paramount for cell survival. Thus, considerable 
cellular resources and mechanisms are dedicated to preventing damage to the DNA from 
endogenous and exogenous insults, such as ROS, replication stress, carcinogens, radiation, etc. 
Genomic alterations are common drivers of tumor initiation and progression, and as such, 
cancer cells are characterized by higher baseline levels of genomic instability (22,234–236). 
Increased genetic instability enables higher mutational rates to promote tumor development, 
heterogeneity and plasticity, however it also renders cancer cells more dependent on certain 
genomic maintenance mechanisms, thereby sensitizing them to targeted therapies against DNA 
replication, repair and checkpoint pathways (237–241). 
A key aspect of genome maintenance is to ensure adequate levels of deoxynucleotide reserves 
and correct incorporation during DNA replication or repair (242,243). Deregulated nucleotide 
metabolism has long been associated with oncogenesis, with studies showing that decreased 
nucleotide pools are sufficient to induce genomic instability and mutagenesis (244–248). 
Nucleotides can be synthesized de novo, regenerated through salvage pathways or scavenged 
from the environment. Given the increased and sustained requirement for nucleic acids in 
tumor cells, salvage pathways alone are unable to satisfy this demand (249). Key enzymes 
involved in nucleotide metabolism, such as TS, RNR, inosine-5’-monophosphate 
dehydrogenase (IMPDH), glycinamide ribonucleotide formyltransferase (GARFT), and 
dihydroorotate dehydrogenase (DHODH), are commonly upregulated in cancer and constitute 
primary targets for anticancer therapy (Figure 7) (250,251,260,252–259).  
Nucleotide metabolism is highly dependent on upstream mTOR and MYC signaling (261,262), 
which control the expression and post-translational modifications of process-initiating enzymes 
such as phosphoribosyl pyrophosphate synthetase 2 (PRPS2), carbamoyl-phosphate synthetase 
2-aspartate transcarbamoylase-dihydroorotase (CAD), and auxiliary enzymes such as PFKFB3 
and MTHFD2, thereby modulating the substrate inputs stemming from the pentose phosphate 
pathway or the folate cycle (119,124,200,263–265). 
Of particular importance is the regulation of dTMP metabolism enzymes, to ensure sufficient 
supplies of dTTP and prevent incorporation of uracil into the DNA during replication, or more 
generally to avoid thymineless death (245,266). In eukaryotic cells, DNA polymerases are 
unable to distinguish between dUTP and dTTP, therefore dUTP/dTTP ratios are tightly 
controlled and kept low, between 0.1% to 3%, to prevent uracil misincorporation (267). 
Misincorporated uracil can also be removed by uracil-N-glycosylase (UNG) and base excision 
repair (268), yet excessive DNA excision can lead to replication stress and genomic instability. 
Mutagenesis caused by RNR overexpression has been shown to stem from an increased 
incidence of erroneous nucleotide incorporation by DNA polymerases (269). High levels of 
dUTPase in cancer patients correlate with poor response to TS inhibitors 5-FU and 
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fluorodeoxyuridine (5-FUdR), and have been shown to become upregulated during the 
development of resistance (270–272). Nuclear localization has been described for both RNR 
and dUTPase, as well as TS, SHMT1, SHMT2α, MTHFD1 and MTHFD2, highlighting the 
importance of local thymidylate synthesis and dUTP exclusion close to DNA replication and 






















Figure 7. De novo purine and pyrimidine synthesis for production of dNTPs. Ribose-5-phosphate from the 
pentose phosphate pathway is transformed into its active form, 5-phosphoribosyl-1-pyrophosphate (PRPP), 
required for both purine and pyrimidine synthesis. Purine synthesis is spatially organized in multienzyme 
complexes called purinosomes and follows a series of ten amidotransferase and transformylation reactions, 
consuming ATP, glutamine, glycine, aspartate, CO2 and 10-formyl-THF, culminating in the formation of inosine 
5'-monophosphate (IMP), the precursor to AMP and GMP. Pyrimidine synthesis is less complex as the base is 
much simpler than purines. First, glutamine is used as a nitrogen donor as carbamoyl phosphate, followed by 
incorporation of aspartate to form carbamoyl aspartate. The enzymes dihydroorotase and DHODH convert it into 
orotate, which is finally conjugated to the ribose from PRPP to form orotate monophosphate (OMP) and UMP. 
UMP can then be used to form dCTP and dTTP (276). The rate-limiting step of dNTP synthesis is catalyzed by 
RNR to form dNDPs, followed by nucleoside diphosphate kinase (NDPK) phosphorylation yielding dNTPs (277). 
Synthesis of dTTP requires additional steps catalyzed by dUTPase, cytidine deaminase (CDA), TS and dTMP 
kinase (TMPK), consuming an additional equivalent of 5,10-meTHF. Adapted and reprinted by permission from 
Springer Nature: Nature Reviews Cancer, Mathews 2015  (248). Copyright © 2015, Nature Publishing Group, a 
division of Macmillan Publishers Limited. All rights reserved. 
 
1.2.2 Altered metabolism and replication stress 
 
Due to its fundamental importance for genome stability, DNA replication is one of the most 
highly regulated processes in cells. Replication stress, i.e., any condition affecting the precise 
and timely progress of DNA replication, is a main source of genomic instability in cancer cells 
(278–283). Histone and dNTP shortages, hard to replicate sequences, and collisions between 
replication and transcriptional machineries can all cause replication stress (244,279). Stalled 
replication forks resulting from these conditions activate the replication stress response, or S 
phase checkpoint, which includes cell cycle arrest, reduced firing of new replication origins, 
activation of dNTP production and DNA repair pathways to enable the restart of stalled 
replication forks and continuation of cell cycle progression (280,283,284). The ataxia 
telangiectasia and Rad3-related (ATR) kinase is the main regulator of the replication stress 
response, and together with mTOR and checkpoint kinase 1 (CHK1), coordinates the timely 
execution of these processes (285–287).  
mTOR plays an important role under replication stress conditions, where it is directly 
phosphorylated by ATR and upregulates expression of CHK1 to enhance the replication stress 
response. Activation of mTOR stimulates anabolic nucleotide synthesis through expression of 
CAD, MTHFD2 and RNR, but also balances catabolic processes including cell cycle arrest, 
cell death and autophagy (201,288). Beyond its canonical function as a main nutrient sensor 
and metabolic modulator, mTOR also directly regulates cell cycle through the transcriptional 
and translational regulation of cyclins and cyclin dependent kinases (CDKs) (289–294). 
Combination of mTOR inhibitors with traditional chemotherapies inducing replication stress 
such as topoisomerase inhibitors has demonstrated great anticancer activity in vitro and in vivo, 
with several combination regimens currently being tested in clinical trials (295–299). More 
recently, there has been tremendous efforts to selectively target high levels of replication stress 
in cancer cells using ATR-CHK1 pathway inhibitors (241,300,301), broadening our 
therapeutic opportunities via synthetically lethal DNA replication challenges to cancer cells. 
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1.2.3 Homology-directed repair of DSBs 
 
DNA molecules are exposed to various intrinsic and external sources of damage on a 
permanent basis. Therefore, maintenance of genome integrity via prompt and accurate DNA 
damage repair is crucial for cells to ensure passing on intact genetic code to the next generation 
of cells and prevent the rise of genetic abnormalities (234,302). Upon DNA damage, cells 
activate different signaling cascades eliciting specific repair machineries depending on the type 
of damage incurred.  
DSBs are particularly toxic DNA lesions, which can lead to replication stress and cell death if 
left unrepaired (303–305). When DSBs arise, cells can choose between two main repair 
mechanisms: non-homologous end joining (NHEJ) or homology-directed repair, also called 
HR repair (Figure 8) (306–308). The choice of pathway is largely controlled by cell cycle 
phase-dependent DNA end-resection mechanisms which commit the repair to the error-free 
HR pathway when a sister chromatid template is present in S and G2/M phases, or relegate it 
to error-prone NHEJ which directly ligates the DSB ends and generates potentially mutagenic 
insertions and deletions (309,310).  
DDR signaling is orchestrated by a family of phosphoinositide 3-kinase (PI3K)-related kinases: 
DNA-PK, ATM and ATR (311). Repair of DSBs involves mainly ATM and DNA-PK 
signaling, with activation of ATM by the DNA damage sensing complex Mre11-Rad50-Nbs1 
(MRN) and subsequent DNA end-resection initiating HR repair (308,310,311). Deregulations 
in DNA repair pathways, including mismatch and HR repair mechanisms, are common in 
cancer and contribute to their development (234,312). Efforts to exploit these DDR defects in 
cancer therapy have proven extremely successful under certain genetic and cellular contexts, 
however the rise of resistance severely hinders the clinical benefit of these therapies 
(241,313,314). New approaches to expand the scope and benefit of therapeutic strategies which 
target the DDR and HR deficiency hold a transformative potential for cancer patient care.   
The strong link between DNA repair and cellular metabolism has become gradually more 
apparent in recent years, particularly in cancer cells, where metabolic deregulations have been 
shown to both promote mutagenic DNA damage as well as support DNA repair pathways 
(Figure 9) (315,316). Many new metabolic players have been identified as having promoting 
roles in DSB repair (11,317–319), either through direct interaction with core DNA repair 
proteins, modulation of nucleotide pools, or regulation of chromatin remodeling via epigenetic 
markers (316). 
 






















Figure 8. Choice of repair pathway for DSBs. While NHEJ proteins Ku70/Ku80 and 53BP1 bind DSBs across 
the cell cycle by default and prevent DNA resection, BRCA1 acts as a repressor of 53BP1 in S and G2/M phases 
to promote HR repair. The endonuclease activity of Mre11 then initiates resection together with CtIP, which is 
further extended by exonuclease 1 (EXO1) and the DNA2-Bloom syndrome protein (BLM) heterodimer, releasing 
the Ku complex from the DNA. The ssDNA overhangs are rapidly bound and stabilized by RPA, which is later 
displaced by RAD51 with the help of mediators BRCA2, PALB2 and the BRCA1–BRCA1-associated RING 
domain protein 1 (BARD1) complex. The RAD51 filaments are then able to guide homology query of the genome 
and strand invasion. Following homology pairing and nascent strand synthesis by DNA polymerases δ and ε, D-
loop structures are primarily resolved by synthesis-dependent strand annealing (SDSA), which does not involve 
cross-over and thus prevents loss of heterozygosity. Other resolution modalities exist such as double Holliday 
junctions which promote crossovers during meiosis, as well as backup yet error-prone long-tract gene conversion 
(LTGC) and break-induced replication (BIR). Reprinted by permission from Springer Nature: Nature Reviews 






Proper maintenance of nucleotide pools is particularly important for DNA replication, but is 
also necessary for repair DNA synthesis, as shown by the cellular need to produce dNTPs at 
DNA damage sites via the recruitment of RNR and thymidylate kinase (TMPK) for example 
(245,274,288). While the relative amount of nucleotides required for repair is small compared 
to DNA replication demands, local dNTP concentration is critical as cells cannot rely solely on 
nucleotide diffusion to ensure adequate repair. In line with this, de novo dNTP production has 
been identified as a key factor in the choice of DSB repair pathway, with HR relying more 
heavily on RNR activity and nucleotide synthesis than NHEJ, as it involves more extensive 
DNA synthesis (320). Moreover, upon DNA damage, ATM activates G6PD to promote 
metabolic rewiring towards the PPP to create more nucleotide precursors, while radioresistant 
cancer cells have been shown to upregulate GS to divert glucose and glutamine metabolism 
towards the production of dNTP (321,322). Finally, both phosphoglycerate mutase 1 (PGAM1) 
and PFKFB3 have also been found to regulate dNTP pools: PGAM1 through modulation of   
3-PG/2-PG balance in favor of PPP, and PFKFB3 by recruiting RNR to DSB sites (319,323).   
Other enzymes have been shown to have direct effects on DNA repair factors. In fact, some 
enzymes can have different effects on separate fronts, such as PGAM1, which in addition to 
supporting PPP, can indirectly modulate CtIP degradation via 3-PG inhibition of 6-
phosphogluconate dehydrogenase (6PGD) (323). Another example is PKM2, which is retained 
in the nucleus following DSB-induced ATM phosphorylation, and contributes to the 
phosphorylation and activation of γH2AX and CtIP to amplify DDR signaling and HR repair 
(317,324). Besides glycolytic factors, ornithine decarboxylase (ODC) is the rate-limiting 
enzyme in polyamine production and is commonly upregulated in cancer, in part due to 
polyamines promoting HR via RAD51-mediated strand invasion and contributing to 
chemotherapy resistance (325,326).  
Finally, chromatin accessibility and epigenetic remodeling are heavily dependent on metabolic 
input and can also influence the choice of repair pathway, either through direct modulation of 
chromatin remodelers or the availability of methyl- and acetyl-group donors necessary for these 
reactions. Acetyl-CoA producing enzyme ATP-citrate lyase (ACLY) is overexpressed in 
tumors, is activated by ATM and AKT following IR and localizes to the nucleus to supply 
acetyl-CoA at DSB sites and favor BRCA1 recruitment over 53BP1 by histone acetylation, 
thus promoting HR (327–330). Accumulation of oncometabolites 2HG, succinate and fumarate 
inhibit lysine demethylases (KDMs) resulting in histone hypermethylation which prevents 
recruitment of HR DNA repair factors (331–336). Increased glucose and glutamine metabolism 
result in higher N-acetyl-glucosamine (GlcNAc) production and protein O-GlcNAcetylation, 
which activates repair-promoting factors such as enhancer of zeste homolog 2 (EZH2), a 
histone-lysine N-methyltransferase responsible for pro-NHEJ H2K27 methylation (337). 
From all this evidence, it is clear that metabolic rewiring in cancer cells protects them against 
radio- and chemotherapy by increasing their DNA repair potential, and thus presents a 






Figure 9. Metabolic modulation of DSB repair. The interplay between DNA repair and metabolism can be 
organized into three main types: (a) dNTP pool regulation, (b) direct involvement in DNA repair, and (c) regulation 
of epigenetic chromatin remodeling. 6PGD, 6-phosphogluconate dehydrogenase; ACLY, ATP-citrate lyase; 
ATM, ataxia-telangiectasia mutated kinase; BRCA1, breast cancer type 1; CtIP, CTBP-interacting protein; DNA-
PKcs, DNA-dependent protein kinase catalytic subunit; EZH2, enhancer of zeste homolog 2; G6PD, glucose-6-
phosphate dehydrogenase; GS, glutamine synthetase; KDMB2/4B, lysine demethylases 2B and 4B; PGAM1, 
phosphoglycerate mutase 1; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; PKM2, pyruvate 
kinase M2; RNR, ribonucleotide reductase; SIRT1, NAD-dependent deacetylase sirtuin-1; TMPK, thymidylate 
kinase. Reprinted from Moretton & Loizou, 2020 (316). Copyright © 2020. Published by MDPI. 
 
 
1.3 COMBINATION STRATEGIES TARGETING THE DDR IN CANCER 
TREATMENT 
 
1.3.1 Radiosensitization  
 
Radiation therapy, or radiotherapy, constitutes one of the most established and successful 
anticancer therapies still used to this day. Ionizing radiation (IR) creates a variety of DNA 
lesions which activate cell cycle arrest and, if left unrepaired, can cause cell death (338,339). 
As such, it is particularly detrimental for rapidly dividing cells such as tumor cells, but also 
normally renewing healthy tissue like intestinal epithelia and hematopoietic cells. This 
unintended toxicity is often dose limiting, with suboptimal radiation doses potentially incurring 
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in further mutagenesis, thus promoting the emergence of resistance mechanisms and tumor 
escape (340). The more radiosensitive tumors are relative to the surrounding normal cells, the 
better the therapeutic effect (341). Although much emphasis has been put on protecting the 
healthy tissue (341), an attractive and complementary alternative would be to disable DNA 
repair mechanisms specifically in cancer cells to render them incapable of coping with 
radiation-induced DNA damage.  
Radiotherapy induces many different types of genomic lesions, by directly damaging the 
phosphodiester backbone of DNA, or indirectly via the creation of free radicals and ROS 
(339,342). While single strand breaks (SSBs) are more frequent, double strand breaks (DSBs) 
have been demonstrated to be the most lethal (303–305). As mentioned previously, the DNA 
damage response (DDR) to DSBs preferentially involves the error-free HR pathway when a 
sister chromatid is available to serve as template for repair in late S an G2/M phases. Therefore, 
cancers which are HR-deficient can be intrinsically more sensitive to radiotherapy, while HR-
proficient tumor cells may become sensitized by concomitant targeting of HR-supporting 
pathways. Combining conventional chemotherapy, as well as targeted DDR inhibitors, with 
radiation therapy has proven successful in increasing its effectiveness (343,344). However, 
many hypoxic solid tumors present a particular challenge as their low-oxygen niche affects 
radiation efficacy by reducing the amount of oxygen free radicals produced (345), which is 
why multiple oxygen therapeutic compounds are currently under clinical investigation to 
overcome this issue (346–349).  
Metabolic rewiring has been shown to mediate radiotherapy resistance by promoting a 
glycolytic phenotype, allowing cancer cells to thrive in hypoxic conditions (350,351). Thus, 
targeting glycolysis which is crucial for energy production in proliferating tumor cells via one 
of its main regulators in cancer, PFKFB3, represents a promising therapeutic avenue to expand 
the range and improve the selectivity of current treatment options, even for slow-growing 
cancers (78,352–355).    
 
1.3.2 Pioneer and new DDR synthetic lethal strategies in the clinic 
 
Cancer development is the result of a progressive multistage accumulation of genetic 
mutations, yet previous studies have shown that cancer survival can often be affected by 
targeting a single oncogene, a phenomenon known as oncogene addiction (356–359). 
Oncogene addiction has been the target of many anticancer strategies, with targeted therapies 
being adopted as standard-of-care anticancer treatment and proven successful even against 
tumors which fail to respond to standard chemotherapy. Nevertheless, precision genotype-
targeted cancer treatments are often limited by the rapid development of resistance and patient 
relapse. This prompted the exploration of secondary targets which would become required for 
cancer cell viability only in the specific context of the tumor’s mutational landscape, i.e., 
synthetic lethality (360).  
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Since the discovery of genetic alterations as tumorigenic drivers, genes involved in DNA 
synthesis, maintenance and repair have been considered bona fide tumor suppressors, as loss 
of proper DNA metabolism often leads to oncogenic mutations and genomic rearrangements. 
This is well exemplified by familial breast and ovarian cancer driven by BRCA1 or BRCA2 
mutations, both well-known factors of homologous recombination DNA repair pathways, or 
hereditary colorectal cancer caused by defects in mismatch repair proteins (361,362). 
Undoubtedly, the most successful example of synthetic lethality being exploited for anticancer 
therapy is the development of poly-ADP-ribose polymerase (PARP) inhibitors for the 
treatment of BRCA-deficient tumors (313,363,364). Numerous statistical prediction and 
genetic screen studies using RNAi and CRISPR/Cas9 have uncovered additional synthetic 
lethal combinations with great potential for clinical targeting, prominently featuring DNA 
damage sensing and repair pathways (365–368).  
Today, a large fraction of anticancer drugs used in the clinic induce replication stress, including 
traditional genotoxic agents such as topoisomerase inhibitors and platinum compounds, as well 
as antimetabolites affecting nucleotide synthesis. Moreover, increasing the replication stress 
burden by the combined action of genotoxic drugs and nucleotide analogues has shown 
increased anticancer efficacy (369). However, the activation of cell cycle checkpoints in 
response to these treatments does not necessarily translate into cancer cell death. Due to their 
high intrinsic load of oncogene-induced replication stress, cancer cells are particularly reliant 
on proficient replication stress response mechanisms to survive under high replication stress 
conditions, achieved by overexpression of CHK1 and RNR for example (244,370,371). As 
replication stress is primarily detected by ATR, which also coordinates the mitotic entry 
checkpoint, loss of ATR in high replication stress conditions would remove the barriers 
preventing mitotic catastrophe and cell death (372–375). Indeed, tumors with high levels of 
replication stress have been shown to be particularly dependent on ATR signaling for survival, 
prompting the development and clinical evaluation of various ATR and CHK1 inhibitors (376–
379). Based on this observation, levels of CHK1 in cancer cells have been used to predict 
response to ATR inhibition, identifying hematological cancers as particularly good candidates 
for ATR inhibition therapy, given their high expression of CHK1 (380–383). Further studies 
will be needed to evaluate the potentially beneficial combinations of ATR inhibitors beyond 
existing chemotherapies, particularly in the context of recent metabolic targets such as IDH, 
PFKFB3, PKM2, SHMT1 and MTHFD2 (34,167,384–386), in hematological malignancies as 




1.3.3 Therapeutic trends in glycolysis and one-carbon metabolism 
 
1.3.3.1 PFKFB3 and glycolytic inhibitors 
 
The Warburg effect constitutes the most predominant metabolic hallmarks differentiating 
cancer cells from healthy tissue. Consequently, sizable efforts have been directed towards 
targeting increased glycolysis and lactate metabolism in cancer therapy (387–391). 
One of the first and best characterized glycolytic inhibitors is 2-deoxyglucose (2-DG), which 
is phosphorylated by hexokinase (HK) into a non-metabolizable product that accumulates in 
the cells and inhibits HK to reduce glucose uptake (392). While preclinical evaluation of 2-DG 
showed promising antiproliferative effects, clinical use of this drug was limited by 
hypoglycemic toxicity, a result shared by many other glycolytic inhibitors (393–396). Clinical 
success of glucose uptake or lactate production targeting therapies remains limited despite 
encouraging results in preclinical models, highlighting the need for more precise targeting of 
glycolysis in cancer (15,27,389).  
Since the first reports of tumor dependence on PFKFB3 upregulation started to suggest it as an 
attractive anticancer target, there has been a heightened interest in developing and evaluating 
PFKFB3 inhibitors to specifically target cancer cell glycolysis (385). The best-studied small 
molecule inhibitor described to target PFKFB3 is 3PO, which is a potent but poorly soluble 
inhibitor of PFKFB3, making it a difficult candidate for clinical development (73). A derivative 
of 3PO, PFK15, was later developed and shown to have improved pharmacokinetic properties 
and good selectivity over other glycolysis enzymes, demonstrating antineoplastic effects in 
gastric cancer, hepatocellular carcinoma and lung carcinoma in vitro and in vivo models 
(74,81,110). An improved analog of PFK15, PFK-158, has also shown great antitumor efficacy 
in various solid cancer models and displayed promising results in Phase I clinical trials against 
solid tumors (75,76,109,397). As a result of their structural differences, these compounds may 
have diverse pharmacokinetic and activity properties, and thus different effects on cancer cell 
metabolism. Importantly, new evidence has shown that 3PO and its derivatives PFK15 and 
PFK-158 do not bind PFKFB3, and that their anticancer effects may not be PFKFB3-mediated 
(398–400). Another promising class of PFKFB3 inhibitors developed by AstraZeneca 
displayed potent inhibition of PFKFB3 and reduction of F1,6BP production in A549 cells 
(398). While pharmacokinetic profiling of their lead compound showed acceptable properties 
(e.g., high oral bioavailability and moderate half-life), selectivity against the closely related 
PFKFB4 isoform was not reported and in vivo efficacy has yet to be determined. Numerous 
other efforts to develop PFKFB3 inhibitors have also contributed to our understanding of SAR 
and different inhibitory modalities, and highlight the need for compounds with improved 
isoform selectivity and in vivo stability (68). Studies describing PFKFB3 inhibitors in 
sensitizing or synergistic combinations with other chemotherapies indicate that these 
compounds may have great adjuvant applications, and endorse the continued development of 
structurally diverse PFKFB3 inhibitors to expand the repertoire and personalization potential 
of future therapeutic strategies (385).  
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1.3.3.2 MTHFD2 and serine/one-carbon metabolism inhibitors 
 
Targeting one-carbon metabolism led to the first chemotherapeutic agents in the 1950’s and 
60’s, some of which are still used today, such as methotrexate, pemetrexed and 5-FU. 
Overexpression of DHFR and TS, as well loss of FPGS and RFC function, are common 
mechanisms of acquired resistance to these antifolates. Moreover, their therapeutic efficacy is 
substantially limited due to toxicity caused by inhibition of one-carbon metabolism in non-
transformed dividing cells, such as those in the intestinal lining and bone marrow, resulting in 
gastrointestinal side-effects, anemia, and compromised immunity. To curb these adverse 
effects, rescue therapy with 5-formyl-THF (known as folinic acid or leucovorin) is commonly 
given together with antifolate treatment, yet their therapeutic index remains moderate.  
Given the increased dependence of tumor cells on this pathway, targeting de novo serine 
synthesis or mitochondrial folate metabolism would be a viable solution to selectively target 
one-carbon metabolism in cancer (401,402).  
As mentioned previously, the serine synthesis promoting enzyme PHGDH is commonly 
upregulated in cancer via copy number gain or as a result of oncogenic ATF4, NRF2 and 
hypoxic signaling (126,168,403–405). PHGDH inhibitors have been developed and shown to 
successfully suppress serine synthesis and cancer cell proliferation in vitro and in vivo (406–
408), however they display poor cancer selectivity and affect the central nervous system 
(409,410). 
More promising proof-of-concept studies focusing on targeting SHMT1 and MTHFD2 have 
demonstrated great potential and selective anticancer efficacy in in vivo models 
(181,210,222,230), yet have also indicated that a complete inhibition of one-carbon metabolism 
may only be achieved by concomitant targeting of multiple enzymes. Thanks to its cancer-
enriched profile, MTHFD2 remains an optimal candidate for development of inhibitors (207). 
A comprehensive comparison of MTHFD1, MTHFD2 and MTHFD2L crystal structures and 
homology models (401,411), together with our group’s recent determination of MTHFD2 
crystal structure (412), have made great strides towards reaching this goal. While the cofactor 
binding site seems to be highly conserved between these enzymes and among other 
NAD/NADP-binding proteins, and is thus unsuitable for inhibitor development, the substrate 
binding pocket contains a few residues which vary between MTHFD1 and MTHFD2, and 
could prove useful to achieve selectivity. Although the recent approval of personalized 
therapies targeting metabolic mutations such as IDH inhibitors has caused much excitement 
and renewed hopes, resistance has already been described through additional mutation of the 
target (413). 
Taken together, these efforts to target metabolic pathways expose the need for complementary 
combinatorial strategies to prevent resistance and improve efficacy, and highlight the need to 




2 DOCTORAL THESIS 
 
2.1 RESEARCH AIMS 
 
In recent years, both PFKFB3 and MTHFD2 have been extensively validated as attractive 
anticancer targets, due to their overexpression in tumors, their various described roles 
supporting cancer progression and their negative association to disease prognosis 
(101,207,210,401,414).  
PFKFB3 is a vital regulator of glycolysis with the highest kinase-to-phosphatase activity ratio 
among the PFKFB isoforms, which promotes high glycolytic rates (60). Exhaustive studies 
have shown that cancer cell growth, proliferation and metastasis are stimulated when PFKFB3 
is overexpressed or activated (80,414). More recently, researchers have linked glycolysis and 
PFKFB3 to DNA repair mechanisms, which implied yet another role for PFKFB3 in supporting 
genome stability (124,125). 
MTHFD2 is canonically an enzyme of mitochondrial one-carbon metabolism; an oncofetal 
protein normally expressed only during embryogenesis, yet commonly reactivated in cancer 
cells (386). MTHFD2 has also been found to localize to the nucleus in proximity to DNA 
replication sites (211). Analysis of publicly available gene expression datasets revealed that 
MTHFD2 is overexpressed in cancer patients resistant to radiotherapy (415), with data from 
our group showing that depletion of MTHFD2 in cancer cells results in DNA damage, 
suggesting a more direct role for MTHFD2 in genome maintenance. 
New therapeutic strategies are needed to improve the prognosis of cancer patients. Based on 
our preliminary data, we hypothesized that both PFKFB3 and MTHFD2 could also support 
proliferation and cancer cell survival via novel functions linked to DNA repair and genome 
stability. Therefore, the specific aims of this thesis were designed to 
(1) characterize the roles of PFKFB3 and MTHFD2 in nucleotide metabolism, DNA 
replication and HR in cancer cells, and 
(2) develop, validate and benchmark potent inhibitors for therapeutically targeting 
PFKFB3 and MTHFD2 in neoplastic malignancies. 
These aims were addressed in the component papers of this thesis and guided the outstanding 
research questions posed in each of the studies as follows: 
Paper I 
• Does PFKFB3 support DNA synthesis only through its effect on glycolysis, or does it have a 
more direct role? 
• Does the genome stability supporting function of PFKFB3 require its enzymatic activity? 
• How does PFKFB3 interact with DNA synthesis and repair enzymes to support this role? 
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• Can the development of more potent and selective PFKFB3 inhibitors aid in uncovering new 
target biology? Does PFKFB3 inhibition phenocopy the depletion of PFKFB3 by RNAi? 
• Can PFKFB3 inhibition be used to sensitize cancer cells to therapies targeting DNA stability? 
Paper II 
• Can the co-crystal structure of LY345899 in the MTHFD2 substrate-binding site reveal new 
insights over existing homology models to guide drug development? 
• Is there an effect of co-factor binding on substrate affinity and enzyme activity? How does 
co-factor preference relate to the physiological subcellular location of MTHFD2? 
• What differences, if any, between MTHFD1 and MTHFD2 could be exploited to develop 
isozyme selective inhibitors? 
Paper III 
• Is MTHFD2 enzymatic activity needed for its role in genome stability? What stage of the 
DNA life cycle is MTHFD2 crucial for? 
• Can specific metabolites rescue the phenotype upon loss of MTHFD2, and can they hint at 
the pathway deregulations causing the observed genetic instability? 
• How can structure-activity relationship models of MTHFD2 improve the design of our first-
in-class substrate-based inhibitors? 
• Can potent MTHFD2 inhibitors identified by biochemical, cellular and target engagement 
profiling confirm the emerging role of MTHFD2 in replication stress? Do the results reflect 
biochemical potency rankings, and can these inhibitors be used to reveal new target biology? 
• What is the cell killing mechanism behind MTHFD2 inhibitors? Does this phenotype follow 
the target’s cancer-enriched expression profile?  
• How can we exploit these mechanistic insights to devise rational therapy combinations? 
• Do MTHFD2 inhibitors display in vivo antitumor efficacy? How do they compare to standard 
of care compounds? 
Paper IV 
• Is MTHFD2 involved in other genomic maintenance processes besides replication? 
• How is MTHFD2 modulated upon DSB DNA damage? 
• Can depletion of MTHFD2 potentiate IR-induced DNA damage?  
• Where in the DDR cascade does MTHFD2 come in? 





The methods and approaches used throughout the studies comprised in this doctoral thesis were 
highly multidisciplinary and strengthened our research findings from different technical 
perspectives, including structural biology, biochemistry, medicinal chemistry, molecular and 
cell biology, as well as translational pharmacology.       
Detailed descriptions of all the techniques used in this doctoral project can be found in the 
individual study publications and manuscripts. Therefore, only key research-area specific 
methods and considerations are discussed below. 
 
2.2.1 Cellular thermal shift assay (CETSA) 
 
The ability to study protein-inhibitor interactions under physiological conditions is a valuable 
and integral part of drug development, not only to directly confirm target engagement, but also 
as a tool to deconvolute target biology.  
Thermal shift assays (TSAs) are used to measure changes in the thermal stability of proteins 
against denaturation in response to different conditions, such as ligand concentration, pH, 
sequence mutations, etc. The thermal unfolding of a protein can be followed over a temperature 
gradient using differential scanning fluorometry (DSF) (416), producing a melting curve from 
which the protein’s melting temperature (Tm) can be determined. It has long been established 
that ligand binding modulates the thermal stability of proteins (Koshland, 1958; Kranz and 
Schalk-Hihi, 2011), either destabilizing it or more often by increasing its thermal stability, 
resulting in a measurable shift of the melting temperature (ΔTm).  
The cellular thermal shift assay (CETSA) was developed to assess protein thermal stability 
changes directly in living cells, whereby whole cells or cell lysates, and not just purified 
proteins, are incubated with a ligand and subjected to a thermal gradient to assess target protein 
unfolding in its native environment (417). The idea is that ligand-stabilized proteins will resist 
denaturation and stay in solution while unbound proteins will aggregate and precipitate. 
Subsequent quantification of the soluble protein fraction by Western blot, amplified 
luminescent proximity homogeneous assays (e.g., AlphaScreen®) or mass spectrometry can 
determine the extent to which ligand-binding affects native protein unfolding (Figure 10). 
This method has several advantages over traditional TSA methods, namely that it requires no 
ligand modification (e.g., linker attachment), no cloning work to introduce reporter tags on the 
protein, and no specialized equipment besides a polymerase chain reaction (PCR) machine, a 
table-top centrifuge and high affinity antibodies against the target (418). As a label-free 
method, CETSA can be applied to a wide range of cells including in vitro cells from culture, 
ex vivo and in vivo xenograft material, as well as primary tissue samples from patients. It can 
be adapted to automated and high-throughput formats, thus making it suitable to directly screen 





















Figure 10. Sample preparation for CETSA experiments. ITDRF: isothermal dose-response fingerprint. Briefly, 
cells or cell lysates were incubated with test compounds or vehicle controls, at a single dose or a dose-range, then 
aliquoted and heated to different temperatures, and finally centrifuged to separate the aggregates from the soluble 
protein fraction. All buffers were complemented with protease inhibitors to minimize protein degradation during 
sample preparation. Created with BioRender.com 
 
Despite its many virtues, some limitations still remain, in particular pertaining to its target- and 
ligand-specific optimization as well as the detection and accurate quantification of stabilized 
proteins. While high affinity antibodies against well-known proteins are readily available, 
newer and perhaps understudied targets might not have suitable antibodies to reliably make use 
this method (418). One workaround could involve tagging proteins of interest with reporter 
groups, at the risk of dramatically reducing the number of cells in which the assay could be 
performed. Unbiased methods such as quantitative mass spectrometry are increasingly being 
used to assess target protein stabilization, even when the putative targets are unknown a priori, 
however this incurs significant cost and effort (419,420).    
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Although the technique has a high degree of reproducibility and false positives are uncommon, 
it is possible for a compound to bind proteins in the same pathway or in the same protein 
complex as the intended target and manifest as direct target engagement even if it does so via 
indirect effects. Complementary use of intact cell and cell lysate CETSA may contribute 
additional layers of information regarding indirect effects on protein complexes as they are 
disrupted in lysate conditions, as well as help determine compound uptake or membrane 
permeability properties.  
 
2.2.2 Direct repeat green fluorescent protein (DR-GFP) assay 
 
To investigate molecular deregulations affecting the fidelity and efficiency of DSB repair, 
various GFP-based reporter systems have been specifically developed to study and differentiate 
between defined repair outcomes such as HR, NHEJ and single strand annealing (SSA). These 
reporters all use rare-cutting endonucleases, mainly I-SceI, to induce DSBs and then monitor 
their repair (421).  
Among the most commonly used tools to study DSB-induced HR activity is one such reporter 
system, DR-GFP, which measures GFP fluorescence as a readout of HR capacity (Figure 11)  
(422). The reporter plasmid contains a full-length GFP sequence with an I-SceI cleavage site 
affecting the open reading frame (ORF), as well as an additional GFP gene fragment with the 
correct ORF sequence, which cannot produce functional GFP protein but serves as a template 
to restore the upstream full-length sequence via gene conversion. In cells which stably express 
the reporter plasmid, the GFP readout is measured by transiently transfecting I-SceI and 
allowing 2-3 days for the cells to complete the repair, depending on the cell type (421). The 
GFP readout is commonly measured by flow cytometry, but can also be quantified by high-
throughput immunofluorescence microscopy or even by PCR amplification of repair products 
using primers flanking the I-SceI cleavage sites (421). Recent developments in CRISPR/Cas9 
gene editing technology have taken these assays to the next level, allowing the precise 
introduction of SSBs and DSBs at desired loci to study their repair (423).  
One of the main limitations of the assay is the low frequency at which these cleavage and repair 
events occur, which result in the amount of GFP+ cells after DSB induction ranging between 
1% and 5%. Furthermore, since the frequency of DSB repair events is directly dependent on I-
SceI transfection efficiency and cell survival, ways to standardize or control for these 
parameters may be required, especially when comparing results between different cell lines. 
An example of such a control would be to perform parallel co-transfection of I-SceI with a 
second vector containing mCherry or DsRed, or use I-SceI vectors in which the I-SceI protein 
is tagged with a reporter marker such as hemagglutinin (HA) which can be used to measure 
expression levels by Western blot with anti-HA antibodies (424). In our experiments, we 
believe such controls were not strictly necessary as we only used U2OS cells, which showed 
little variation in transfection efficiency between replicates, and always prepared transfection 











Figure 11. Graphical representation of the direct repeat GFP (DR-GFP) reporter assay. The reporter plasmid 
contains a modified GFP sequence containing an I-SceI site and in-frame stop codons (SceGFP), together with an 
internal truncated GFP fragment (iGFP). The cells can use the iGFP as template to repair the endonuclease-induced 
DSB by HR gene conversion, resulting in a functional GFP gene which can be used to quantify HR-proficient cells 
by flow cytometry or immunofluorescence microscopy. Created with BioRender.com 
 
Another consideration is the tradeoff between increasing transfection efficiency and toxicity. 
To optimize the number of cells seeded for maximal transection efficiency while ensuring 
enough cells available for flow cytometry after 3 days without reaching confluency, we opted 
for a low-throughput 6-well format. While this allowed us to harvest enough cells for proper 
statistical analysis of the low frequency events, it came at the cost of higher usage of expensive 
transfection reagents.  
 
2.2.3 DNA fiber assay 
 
Understanding replication stress response mechanisms and perturbations has particularly 
important implications for genetic instability in the context of cancer establishment and 
progression (279,379). The DNA fiber assay is one of the most powerful and widely used tools 
to study perturbations of replication dynamics at the single-molecule level. This technique 
relies on cells being able to incorporate nucleotide analogs into nascent DNA and is commonly 
used to evaluate how genotoxic agents affect DNA replication (425,426). 
In short, dividing cells are sequentially pulse labeled with two different halogenated pyrimidine 
nucleoside analogs, which get readily incorporated into replicating DNA (427). The nucleoside 
analogs 5-chloro-2′-deoxyuridine (CldU) and 5-iodo-2′-deoxyuridine (IdU) are commonly 
used and are added directly to the culture medium. After incubation with the first analog (e.g., 
CldU), the cells are carefully washed with pre-warmed medium, and incubated with the second 
analog (e.g., IdU). The concentration of the second analog should be approximately 10-fold 
higher than the concentration of the first analog to ensure that the second analog is able to 
displace any remaining initial analog that was not removed during the washing steps. Labeling 
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and washing steps should be performed as quickly and gently as possible, to prevent major 
disruption of ongoing replication. After labeling, cells are harvested and lysed, with DNA being 
spread or combed onto microscope slides, then fixed and immunostained with anti-CldU and 
anti-IdU antibodies (Figure 12). Imaging of the DNA fibers is performed by fluorescence or 
confocal microscopy, where special attention should be put into imaging only the regions 
where the fibers are well separated and not entangled, and to capture images in different areas 
along the slide as only one region may not provide representative data. Finally, fiber track 
length is manually scored using ImageJ or automatically by software algorithms, depending on 
the uniformity of the DNA fibers. A minimum of 100 fibers per condition should be quantified 
















Figure 12. Schematic of the three main methods to prepare DNA fibers. (A) DNA combing: cells are 
resuspended and lysed in an agarose plug, then DNA is combed with a combing machine onto a silanized coverslip. 
(B) Microfluidic-assisted replication tract analysis (maRTA): cells are embedded and lysed in an agarose plug, 
then DNA is stretched using a polydimethylsiloxane (PDMS) patch containing small capillaries. A drop of isolated 
DNA is added at one of the capillary ends of the PDMS patch, which stretches the DNA onto the silanized coverslip 
using capillary force. (C) DNA spreading: a drop of prelabeled cells is transferred to a positively coated microscope 
slide and lysed. The slide is then tilted at a 25–60 degrees angle to allow DNA spreading down the slide. Following 
spreading by any of these methods, DNA is fixed and immunostained. DNA fiber images can then be acquired 
using a fluorescent microscope. Reprinted from Quinet et al., 2017 (425),with permission from Elsevier. Copyright 
© 2017 Elsevier Inc. All rights reserved. 
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The order and duration of the analog labeling incubations depends on the biological question 
being addressed. The DNA fibers assay is highly versatile in the variety of replication 
parameters it can assess. The original scheme whereby both analogs are added for the same 
amount of time can identify elongating forks, stalled/collapsed forks, initiation events (origin 
firing) and replication collision terminations (Figure 13) (425).  
One of the most important readouts of this assay is the estimation of replication fork velocity. 
After measuring the length of labeled tracts, the values are converted from micrometers (μm) 
into kilobases (kb). For fibers obtained by combing the conversion factor is 2 kb/μm (428), 
while for fibers obtained by spreading, like the ones used throughout this thesis project, the 
conventionally accepted conversion factor is 2.59 kb/μm (429,430). Fork speed can then be 
calculated by dividing the length of the tract by the labeling time (kb/min). Fork velocity can 







Figure 13. Different replication events that can be studied by DNA fiber analysis. Replication parameters 
observed by DNA fiber assay and their interpretations. Reprinted from Quinet et al., 2017 (425), with permission 
from Elsevier. Copyright © 2017 Elsevier Inc. All rights reserved. 
 
One of the main limitations of the DNA fiber technique is that it is delicate and time consuming, 
allowing preparation of only a handful of samples at a time. Compared to DNA combing and 
stretching, DNA spreading requires the least material and equipment, however it still takes two 
full days for sample preparation. Delicate handling of the DNA fibers is paramount to minimize 
breakage. Moreover, spreading DNA using gravity can lead to non-uniform DNA fibers with 
increased risk of fiber entanglement, reducing the number of fibers available for quantification. 
In our studies we were able to improve DNA protection, facilitate fiber elongation and reduce 
reagent volumes by switching from conventional microscope slides to multichannel slides. 
Another drawback of the DNA fiber technology is that it cannot detect ssDNA regions which 
are important intermediates in replication stress mechanisms, such as nuclease resection of 
stalled forks required for restart. The resolution of this assay cannot distinguish these < 1 kb 




2.2.4 Uracil DNA glycosylase (UNG) modified alkaline comet assay 
 
The comet assay, or single-cell gel electrophoresis, is a straightforward and sensitive method 
for measuring DNA strand breaks in cells independent of organism or tissue origin, with 
numerous variations generated since it was first described in 1984 to assess different types of 
damage and repair (435,436). A notable modification was the “alkaline” comet assay which 
uses a higher denaturation pH to convert a wider range of DNA lesions into breaks (e.g., alkali-
labile sites such as alkylated or apurinic/apyrimidinic (AP) sites), thereby making them easier 
to detect (437). Due to its increased sensitivity over the original comet assay, the alkaline 
version is usually preferred. 
The principle behind the technique is the ability of DNA to form supercoiled loops called 
nucleoids when stripped of protein associations (438). Intact DNA retains a compact structure 
while DNA breaks induce a loss of supercoiling and relaxation of the nucleoid structure, which 
can be measured using electrophoresis. To achieve this, cells are suspended in low-melting-
point (LMP) agarose at 37 °C and embedded onto microscopy slides, then lysed with detergent 
and high salt to disrupt DNA-protein binding. In the alkaline version of the assay, nucleoid 
DNA is then denatured in high pH conditions (pH > 13) and subjected to an electric field 
allowing uncoiled and fragmented DNA to migrate away from the main bulk of the nucleoid 
towards the anode. This creates comet-like structures, which are then stained with a fluorescent 













Figure 14. Graphical description of the UNG modified alkaline comet assay protocol. From the moment the 
cells are embedded in the agarose, all assay steps are performed in the dark to minimize photodegradation of DNA. 
Created with BioRender.com 
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The intensity of the comet tail compared to the head is an indication of the number of DNA 
breaks. This is measured either as tail DNA percentage or tail moment, defined as the product 
of the tail length and tail DNA percent (439). The sensitivity of the assay ranges from 
approximately 50 to several thousand breaks per cell, which covers low endogenous DNA 
stress levels as well as high DNA damage levels caused by genotoxic drugs (440,441). 
An important modification of the assay has been the addition of an enzymatic digestion step, 
where the nucleoids are incubated with different DNA repair nucleases to measure specific 
DNA lesions. For example, DNA glycosylases such as formamidopyrimidine DNA 
glycosylase (FPG), 8-oxoguanine DNA glycosylase (OGG1) and uracil-DNA glycosylase 
(UNG) are commonly used in comet assays to study oxidative DNA damage and uracil 
misincorporation (442–444). Although the main utility of this method is to measure DNA 
breaks, several modifications to the assay have enhanced its power to distinguish between SSBs 
and DSBs (e.g.,  2-dimesional two-tailed TT-comet (445)) and even evaluate DNA repair 
mechanisms at specific gene regions (e.g.,  Comet-FISH (446)). 
Despite its relative simplicity and versatility, the main limitations of the comet assay remain 
how delicate, low throughput and labor-intensive it is. From cell culture to slide storage and 
image acquisition, every step should be carefully executed to avoid high background DNA 
damage levels, including working in the dark for several hours at a time. Cells must be low 
passage, as cells cultured for more than 12-15 passages tend to display higher basal DNA 
breaks that could mask treatment effects. Agarose embedding of the cells is another delicate 
step, as gel temperature should be carefully monitored to prevent additional damage. In 
between incubation steps and during storage coverslips are used to prevent drying of the 
agarose, however improper removal of the coverslip can often result in gel break or detachment. 
Electrophoresis tank space is yet another limiting factor, particularly when experimental 
conditions tend to exponentially increase with the addition of enzymatic digestion steps, 
varying drug concentrations, different timepoints, technical replicates and relevant controls.     
Variability in the comet assay represents another important issue. While intra-laboratory 
reproducibility is typically high, inconsistencies between research groups are common and 
likely due to discrepancies in protocol incubation times, staining, analysis, and other 
experimental parameters (440,447). Comet scoring can also be time-consuming and potentially 
biased if automated software is not employed. Although various high throughput modifications 
have been developed in recent years, scoring remains a prominent bottleneck (448).  
 
2.2.5 Ethical implications 
 
Most of the work presented in this project has been carried out using established cancer and 
non-transformed cell lines, for which no ethical permit is required. The in vivo studies to test 
MTHFD2 inhibitors in xenograft mouse models were performed by trained professionals in 
accordance with ethical permits N217/15 and N89/14.   
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2.3 SUMMARY OF RESULTS 
 
2.3.1 Paper I: Targeting PFKFB3 radiosensitizes cancer cells and suppresses 
homologous recombination 
 
Prior to this study, PFKFB3 had been validated as a promising target to exploit glycolytic 
deregulation in cancer (61,65,77,110,449). Indications of its non-canonical functions in the 
nucleus and on p53-mediated repair of UV lesions (90,124), together with the identification of 
PFKFB3 in genome-wide siRNA screens to detect DDR factors and the observation that 
PFKFB3 was upregulated in radiotherapy-resistant patients (415,450,451), prompted us to 
investigate its potential involvement in the repair of IR-induced DSBs. In this study, we 
reported a novel role for PFKFB3 in HR repair of DSBs in cancer cells and described the 
development of a new PFKFB3 inhibitor, which we used to validate our biological findings.  
First, we assessed whether PFKFB3 was recruited to DSB sites and co-localized with DNA 
damage marker γH2AX upon IR using in situ cell fractionation and confocal microscopy. We 
found that ATM activity, but not ATR or DNA-PK, mediated PFKFB3 recruitment to DSB 
sites. Depletion of γH2AX and MDC1 by siRNA also reduced PFKFB3 co-localization to IR-
induced foci (IRIF). Furthermore, we observed that PFKFB3 foci co-localized with important 
DSB repair factors, and that depletion of PFKFB3 abolished recruitment of HR factors 
BRCA1, RPA32 and RAD51 to damage sites. To confirm functional engagement of PFKFB3 
in HR we performed DR-GFP assay in PFKFB3-silenced cells, showing that loss of PFKFB3 
activity reduced HR potential by 60% in a manner unexplained by changes in cell cycle 
distribution. Clonogenic survival assays were performed to determine the effects of PFKFB3 
depletion in combination with IR on cancer progression, demonstrating that concomitant 
PFKFB3 silencing significantly enhanced radiosensitivity by approximately 6-fold compared 
to cells treated only with IR. 
In an attempt to pharmacologically recapitulate the HR effects observed with siRNA depletion, 
we used an established inhibitor of PFKFB3, 3PO. Nevertheless, we could not confirm 
inhibition of PFKFB3 with this compound, nor could we validate the HR effects observed with 
siRNA. Therefore, we established a collaboration with the pharmaceutical company Kancera 
to develop alternative inhibitors, starting with a drug screening campaign of over 50,000 
compounds which yielded over 100 hits with low micromolar to nanomolar IC50 values against 
PFKFB3. Non-ATP competitive hits were progressed along the pipeline and evaluated for 
selectivity against the other PFKFB isozymes, resulting in a class of phenylsulfonamido-
salicylic acids which effectively reduced intracellular F2,6BP levels and cell viability in 
different cancer cells. In parallel, assessment of biophysical and ADME parameters to confirm 
pharmacological suitability of the compounds revealed KAN0438241 and its prodrug 
KAN0438757 (KAN757) as potent and selective representatives of this phenylsulfonamido-
salicylic acid family of PFKFB3 inhibitors. In cells, KAN757 was shown to bind and stabilize 
PFKFB3 using CETSA, with prolonged stability and inhibitory capacity lasting at least 72 h, 
corresponding to the duration of most cellular assays. Finally, selectivity over other kinases 
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beyond the PFKFB isozymes was evaluated, with no significant inhibition being observed for 
KAN0438241 or KAN757 across a panel of 97 distinct kinases.  
To assess whether the HR-supporting role of PFKFB3 was mediated by its kinase activity, we 
repeated some of the key siRNA experiments with KAN757. We found that KAN757 
phenocopied the results observed upon PFKFB3 depletion, namely the impaired recruitment 
of RPA32 and RAD51 to IR-induced DSB sites downstream of MRN signaling and the 
significant reduction of HR potential in DR-GFP assays. Dose-dependent radiosensitization by 
KAN757 was also observed in cancer cells but not in non-transformed cells. 
We hypothesized that PFKFB3 could promote HR repair via effects on nucleotide metabolism, 
which we confirmed by monitoring 5-ethynyl-2′-deoxyuridine (EdU) incorporation into DNA 
following IR-induced damage in the presence of KAN757. Nucleotide production at sites of 
DNA synthesis is mediated by RNR subunit RRM2 (274,288), thus we investigated whether 
PFKFB3 activity affected RRM2 recruitment upon DSB formation. Knockdown and inhibition 
of PKFBF3 by KAN757 prevented RRM2 recruitment to DSB sites to a similar extent than 
ATM inhibition, depletion of RRM2 resulted in a similar decrease of HR activity in DR-GFP 
assays as depletion or inhibition of PFKFB3, and finally a direct interaction between PFKFB3 
and RRM2 could be observed via co-immunoprecipitation, altogether suggesting PFKFB3 
could support HR repair by facilitating local supply of dNTPs. Next, we measured cellular 
dNTP levels upon KAN757 inhibition of PFKFB3, showing significantly reduced nucleotide 
concentrations equally across purine and pyrimidine pools. Moreover, effects of KAN757 on 
DNA replication speed and viability could be rescued by supplementation with nucleosides.  
Taken together, the work presented in this study demonstrated a new HR-promoting role for 
nuclear PFKFB3 regulating local dNTP production via recruitment of RRM2 in response to 
MRN-ATM-γH2AX-MDC1 signaling upon IR-induced DSBs. This study also presented the 
development of a potent, selective and cell active PFKFB3 inhibitor KAN757, and validated it 
as a radiosensitizer with potential implications for the future improvement of cancer therapy. 
 
2.3.2 Paper II: Crystal structure of the emerging cancer target MTHFD2 in 
complex with a substrate-based inhibitor 
 
At the start of this study, MTHFD2 had recently reemerged as a promising anticancer target 
indispensable for cancer cell proliferation, despite having been detected in rapidly proliferating 
embryonic tissue and tumor cells in 1985 (48,176,207,401). In the years since, no MTHFD2 
inhibitors had been described, and attempts to determine the protein’s 3D strcuture had thus far 
relied on sequence homology models based on the structure of the MTHFD1 dehydrogenase-
cyclohydrolase (DC) domain (178,411) and MTHFD2 homologs in bacteria and yeast 
(452,453). In this study we described the first inhibitor to be identified for human MTHFD2, 
and with it, the first crystal structure of MTHFD2. This work provided an important piece of 
structural foundation for drug discovery efforts to be built upon to rationally design potent and 
selective MTHFD2 inhibitors for cancer treatment. 
 
42 
We started by expressing and purifying human MTHFD2 and MTHFD1-DC domain in E. coli, 
and used the commercial NAD(P)H-Glo assay (Promega) to measure their enzymatic activity. 
We then tested a known MTHFD1-DC ligand, LY345899, and found that it also substantially 
inhibited MTHFD2 enzymatic activity with an IC50 value of 663 nM. Target engagement of 
MTHFD2 by LY345899 was first evaluated by DSF, showing strong stabilization of the protein 
with an associated ΔTm of 11 °C. This was then confirmed in cellular lysates with CETSA and 
the drug affinity responsive target stability assay (DARTS), based on the same principle as 
CETSA, but rather than subject the lysates to thermal degradation, the stability of ligand-bound 
proteins is measured in response to protease degradation. Paradoxically, LY345899 did not 
affect cancer cell viability and CETSA in intact cells with LY345899 did not result in MTHFD2 
stabilization, suggesting the compound is poorly permeable. 
High quality crystals of MTHFD2 bound to LY345899 in the presence of cofactors NAD+ and 
inorganic phosphate (Pi) were produced and used to determine the structure of MTHFD2 by 
X-ray diffraction at the European Synchrotron Radiation Facility to a resolution of 1.9 Å. The 
overall homodimeric structure coincided largely with previous models, but identified important 
differences relative to MTHFD1-DC structure that could prove useful to design isozyme 
selective inhibitors. The co-factor binding sites correlated well to known cofactor preference 
(i.e., why MTHFD2 preferentially uses NAD+ and Pi over NADP+), as well as previous 
observations of site-mutants and their effects on enzyme activity. The interactions between 
LY345899 and the substrate binding site revealed various insights on ligand binding modality 
and identified the key residues responsible for substrate binding and enzyme activity. The 
difference in affinity to LY345899 between MTHFD1-DC and MTHFD2 was also reflected 
by the presence of important ligand-binding residues in MTHFD1 which are not conserved in 
MTHFD2. Altogether, these observations provided a sound starting point towards the 
advancement of other substrate-based inhibitors optimized towards MTHFD2 and the 
development of robust structure-activity relationship (SAR) models. 
 
2.3.3 Paper III: Targeting MTHFD2 kills cancer via thymineless-induced 
replication stress  
 
From the literature we found that, while MTHFD2 had been extensively validated in different 
in vitro and AML in vivo models as being crucial for tumor cell proliferation and survival 
(207,210,401), no study had directly assessed whether the enzymatic activity of MTHFD2 was 
necessary for its role in cancer progression. With the structural insights from Paper II, we 
devised point mutations in the substrate-binding pocket of MTHFD2 to abolish its enzymatic 
activity, and performed viability rescue experiments where endogenous MTHFD2 levels were 
depleted and either wild-type or catalytically dead constructs were expressed. We found that 
mutations in the substrate-binding site affected the protein’s ability to rescue the viability 
phenotype. Furthermore, we noticed that depletion of MTHFD2 resulted in increased levels of 
DNA damage marker γH2AX, which could also be restored by overexpression of the wild-type 
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but not the catalytically dead mutant, highlighting the importance of MTHFD2 activity for its 
role in cancer.  
Additional metabolic rescue experiments revealed that the decrease in viability upon MTHFD2 
depletion could be rescued by supplementation of either nucleosides, thymidine and folate, but 
not glycine or hypoxanthine, suggesting that production of CH2-THF by MTHFD2 required 
for de novo thymidylate synthesis is key to supporting cancer cell proliferation. Analysis of 
γH2AX levels across the cell cycle showed that DNA damage upon loss of MTHFD2 
accumulated in S phase, indicative of replication stress and consistent with its association to 
replication sites in the nucleus (211). These observations were confirmed by DNA fiber assays 
showing significantly impaired replication fork speeds in MTHFD2-depleted cells.  
The relatively low potency and poor permeability of LY345899 made it unsuitable to study the 
pharmacological inhibition of MTHFD2 in cells, which encouraged us to develop more potent 
and cell-active MTHFD2 inhibitors. In search of promising compounds for lead optimization 
we screened over 500,000 molecules but found no suitable candidates, which redirected us 
towards a substrate-based drug development approach capitalizing on the structural 
understanding gained from Paper II. Successive rounds of chemical design, synthesis and 
evaluation of biochemical and cellular activity yielded a well-refined SAR model and a series 
of substrate-like compounds with significantly improved potency and cell activity compared to 
LY345899. Three representative MTHFD2 inhibitors (MTHFD2i) in this series, TH7299, 
TH9028 and TH9619, were selected for further biological evaluation and as tools to investigate 
MTHFD2 mechanisms of action. These compounds were confirmed to bind and stabilize 
MTHFD2 using DSF, surface plasmon resonance (SPR), CETSA and DARTS assays, while 
close pathway targets such as MTHFD1L, DHFR, TS, SHMT1 and SHMT2 remained 
unaffected in activity and target engagement assays. Although related isozymes MTHFD1 and 
MTHFD2L were also found to be inhibited by MTHFD2i, CRISPR/Cas9 MTHFD2 knockout 
cells were shown to be orders of magnitude more resistant to TH9619 than MTHFD2 wild-
type cells, providing strong evidence that MTHFD2i-induced cancer cell toxicity is largely 
mediated by on-target MTHFD2 inhibition. 
In a panel of hematological cells including ALL and AML cell lines as well as non-transformed 
lymphoblastoid LCL cells, MTHFD2i displayed particular efficacy in AML cell lines and the 
most cancer-specific profile, compared to the standard of care compound cytarabine (AraC) 
and the antifolate methotrexate which also affected LCL cell viability. Relative to the AML-
specific differentiation agent all-trans retinoic acid (ATRA), MTHFD2i also induced myeloid 
differentiation, while their anticancer efficacy was extended beyond AML to T-ALL Jurkat 
cells, expanding the potential therapeutic applications of these compounds. The cancer-
selective profile of MTHFD2i was confirmed in CCD 841 normal colon epithelial cells and 
CD34+ bone marrow cells from healthy donors, where MTHFD2i had little effect on viability 
compared to a variety of anticancer agents. 
Next, we investigated whether MTHFD2i induced replication stress in cancer cells similar to 
MTHFD2 depletion. We observed that MTHFD2i induced accumulation of DNA damage in S 
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phase, impaired replication fork speeds, led to replication fork collapse and activated intra-S 
phase checkpoint pro-apoptotic signaling. Combination of MTHFD2i with replication stress 
response blockers (e.g., inhibitors of ATR, CHK1, WEE1) synergized to reduce cancer cell 
viability and induce apoptosis. Moreover, we showed that MTHFD2i introduced replication 
stress selectively in transformed cells, while methotrexate and ATR inhibitor affected 
replication fork progression indiscriminately in both normal and transformed cells. In line with 
RNAi data, viability, replication stress and differentiation phenotypes induced by MTHFD2i 
could be completely rescued by addition of thymidine, in contrast to established antifolates and 
ATRA, suggesting a distinct mechanism of action for MTHFD2i via induction of thymineless 
death selectively in cancer cells.  
A consequence of thymidylate depletion is an increased frequency of dUTP misincorporation 
into DNA, which causes replication stress and is deleterious for cells. Hence, we evaluated 
whether MTHFD2i affected genomic uracil misincorporation. Using the modified alkaline 
UNG comet assay and LC-MS measurements of genomic uracil, we confirmed that MTHFD2i 
induced significantly higher levels of uracil in DNA than TS inhibitor 5-FU and standard 
antifolates, and that this effect could also be reversed by thymidine supplementation. Inhibition 
of dUTPase promotes the accumulation of dUTP by preventing its degradation; consequently, 
MTHFD2i and dUTPase inhibition synergized to potentiate uracil incorporation into DNA, 
induce dose-dependent reduction of cancer cell viability and increase apoptosis.    
Evaluation of clinically relevant pharmacological parameters revealed TH9619 to be a 
promising candidate for further translational applications, as it displayed good solubility and 
stability, low plasma protein binding, and had clean selectivity profiles in kinase and safety 
screens. In a xenograft mouse model of AML, TH9619 significantly decreased plasma 
thymidine levels, reduced tumor burden and prolonged survival in a dose-dependent manner, 
outperforming standard of care compound AraC, with CETSA assays confirming intratumor 
target engagement of MTHFD2 in TH9619-treated animals.  
In summary, the findings of this study describe a new role for MTHFD2 in maintaining genome 
stability through supporting de novo thymidylate synthesis for DNA replication in cancer cells. 
This work also presents the development of first-in-class, potent and cell active MTHFD2i with 
promising clinical potential. Extensive chemical and biological characterization of this new 
class of MTHFD2i provides compelling evidence of their antitumor efficacy with a clearly 
defined mechanism of action and a cancer-enriched activity profile, making these compounds 
attractive to improve selectivity and efficacy of current cancer therapy.       
 
2.3.4 Paper IV: Targeting MTHFD2 impairs homologous recombination and 
sensitizes cancer cells to PARP inhibitors  
 
From our lab, two previous genome-wide siRNA screens to identify novel HR repair factors 
independently discovered MTHFD2 among their hits (450,454). Analysis of gene array data 
from radioresistant patients also revealed MTHFD2 mRNA to be upregulated in response to 
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radiotherapy (415). Together with more recent reports of MTHFD2 supporting non-canonical 
nuclear functions (211,212), including our findings from Paper III, the evidence pointed 
towards a potential role for MTHFD2 in HR repair of DSBs. 
To validate in vitro the upregulation of MTHFD2 mRNA upon IR in patients, we monitored 
MTHFD2 protein levels following hydroxyurea (HU)- and IR-induced DSBs in U2OS cells 
and found that both DSB-inducing treatments resulted in accumulation of overall cellular 
MTHFD2 protein levels. Upon inhibition of upstream DDR kinases ATM, ATR and DNA-PK 
prior to IR treatment, we observed that MTHFD2 protein accumulation was abolished in ATM- 
and DNA-PK-inhibited cells, but not in ATR-inhibited cells, consistent with a potential role in 
ATM- and DNA-PK-mediated DSB repair. Using subcellular fractionation, we were able to 
observe a distinct association between MTHFD2 and chromatin in response to IR, which was 
suppressed upon ATM or MTHFD2 inhibition. Taken together, these data supported a role for 
MTHFD2 in DSB repair under ATM signaling control.  
Our hypothesis was that MTHFD2 supported HR repair of DSBs, which we tested by means 
of the DR-GFP assay. Depletion of MTHFD2 drastically reduced HR activity by over 80% in 
U2OS cells, to a comparable extent as loss of the critical HR factor RAD51. We observed that 
HR activity in these cells correlated with MTHFD2 protein levels, recognizing MTHFD2 
expression as a determinant of HR proficiency in cancer cells. Next, we evaluated the effect of 
MTHFD2 depletion on the recruitment of HR repair factors to DSBs, namely RPA32 and 
RAD51. Silencing of MTHFD2 prior to IR significantly decreased the focal accumulation and 
nuclear intensity of both RPA32 and RAD51, implying a role for MTHFD2 in HR upstream of 
DNA resection.  
We then evaluated the effect of MTHFD2 on the late-stage response to IR, including cell cycle 
arrest and clearance of DNA damage. Depletion of MTHFD2 upon IR resulted in a larger 
fraction of cells arrested in G2/M phase and a greater proportion of cells with unresolved DNA 
damage 24 h post-IR as compared to IR-only control samples. Pre-treatment with MTHFD2i 
also induced a dramatic increase in γH2AX levels 24 h post-IR. 
Given the cancer-preferential expression pattern of MTHFD2, we sought to investigate whether 
targeting MTHFD2 could induce cancer-specific HR deficiency and sensitize cancer cells but 
not normal cells to PARP inhibitors. We assessed apoptosis levels in HR proficient THP-1 cells 
upon treatment with MTHFD2i and PARP inhibitor olaparib, as single agents or in 
combination, and found that combination of MTHFD2i and olaparib synergized to induce cell 
death to a much larger extent than either agent alone. Compared to non-transformed LCL cells, 
the synergistic cell killing upon MTHFD2i and olaparib combination was apparent only in the 
transformed cells, in line with our hypothesis that cancer enriched MTHFD2 expression would 
determine sensitivity to the combination treatment. In an animal model of AML, combination 
of MTHFD2i and PARP inhibitor talazoparib synergistically delayed tumor growth at 
concentrations that had no monotherapy effect.  
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In conclusion, this study presents another role for MTHFD2 in genome maintenance, this time 
in supporting ATM-mediated HR repair of DSBs. Moreover, we provide in vitro and in vivo 
evidence to propose targeting of MTHFD2 as a novel strategy to induce HR deficiency 
specifically in tumor cells to further sensitize them to DDR agents such as PARP inhibitors. 
 
2.4 DISCUSSION AND FUTURE PERSPECTIVES 
 
2.4.1 PFKFB3 inhibitors as chemo- and radiosensitizers 
 
When the premise of this thesis was established, PFKFB3 had gained notoriety as an important 
glycolytic regulator in tumors and attempts to develop potent inhibitors with anticancer efficacy 
had already shown promising proof-of-concept results (74,103,110). Nevertheless, the effects 
of different inhibitors were varied and additional nuclear and non-glycolytic roles of the 
enzyme were just starting to be discovered (124), suggesting there was more to the picture than 
we had previously thought. 
Paper I highlighted a previously undescribed role for PFKFB3 in supporting ATM-mediated 
HR repair of IR-induced DSBs by promoting local dNTP production through its interaction 
with RRM2. These findings were in line with known ATM regulation of metabolic rewiring 
and glycolytic pathways to stimulate nucleotide and antioxidant synthesis upon DDR signaling 
(322,455,456).  
Moreover, the development of KAN757 as a potent and selective PFKFB3 inhibitor allowed 
us to investigate the potential of targeting PFKFB3 as a radiosensitizing strategy. As previously 
discussed in this thesis, effective therapeutic radiation doses are often limited in the clinic by 
low normal tissue tolerance (340). Additionally, metabolic alterations that promote glycolytic, 
hypoxic and acidotic microenvironments have recently been implicated in resistance to radio- 
and chemotherapy (86,93,350,351). Our results from Paper I showed that KAN757 could 
preferentially sensitize transformed cells to radiotherapy, likely through combined effects on 
general glycolysis (i.e., energy production, biosynthesis and ROS) and DNA repair via 
PFKFB3-mediated dNTP production at DSB sites. Whereas previous glycolytic inhibitors such 
as 2-DG have not been successful due to their systemic hypoglycemic side-effects (395), 
PFKFB3 inhibitors provide an elegant alternative to target glycolysis and DNA repair 
specifically in cancer cells where PFKFB3 is upregulated. In particular, KAN757 has recently 
been shown to display cancer-specific cytotoxicity on patient-derived intestinal cancer 
organoids, as well as a highly tolerable profile in mouse models without systemic toxicity 
(457), further strengthening the concept of achieving tumor selectivity through the use of 
PFKFB3 inhibitors. 
In view of the high plasticity and adaptability of metabolic pathways in cancer cells, 
combination strategies that target several orthogonal tumor-promoting processes in parallel 
have the potential to improve sensitivity and efficacy, while limiting the emergence of 
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resistance. PFKFB3 inhibition has the potential to enhance the therapeutic benefit of many 
other anticancer strategies beyond radiotherapy (352,355,385).  
Targeting glycolysis concomitantly with receptor tyrosine kinase or serine/threonine kinase 
signaling has been largely explored in the context of constitutive kinase activation driven 
cancers like chronic myeloid leukemia, melanoma and non-small cell lung cancer, as well as 
hormone responsive tumors like breast cancer, with promising results in clinical trials 
(84,97,102,103,111). Although new data suggests that the compounds used in these studies 
(3PO, PFK15 and PFK-158) may inhibit glycolysis via PFKFB3-independent mechanisms 
(398–400), similar synergies could still hold true for PFKFB3 inhibitors. 
Gynecological and colorectal cancers have also been shown to benefit from PFKFB3 inhibition 
in combination with platinum drugs, as PFKFB3 mediates platinum resistance (86,109,458). 
While platinum drugs acetylate PFKFB3 to disrupt nuclear localization signal activity and 
mediate post-exposure resistance through its cytosolic function (86), pre-treatment with 
PFKFB3 inhibitors prior to platinum drug therapy could also improve therapeutic outcome by 
disabling HR repair as described in Paper I, which is a key pathway involved in the repair of 
deleterious platinum-induced interstrand crosslinks (ICLs) (459). Indeed, a recent report 
validated this hypothesis by showing that reduced PFKFB3 activity resulted in increased 
platinum sensitivity of endometrial cancer cells in vitro and in vivo (125). Furthermore, AMPK-
mediated glycolysis switch promoting mitotic arrest escape upon microtubule poisons could be 
another way in which PFKFB3 inhibition may synergize with established chemotherapeutics 
to enhance efficacy and prevent tumor escape (93). 
Moreover, additional combination strategies could be devised by exploiting the cancer’s own 
ability to rewire its metabolism and modulate its microenvironment. For example, therapies 
which induce hypoxic conditions would increase cellular dependence on upregulation of 
glycolysis, making cancer cells particularly sensitive to PFKFB3 inhibition. Modulating the 
pH of the tumor microenvironment to counter lactic acidosis would also reduce the resistance 
to glucose deprivation induced cell death and provide a context where PFKFB3 inhibition 
would have maximal effect on cancer killing (460,461). Finally, through its effects on immune 
and angiogenic processes, PFKFB3 inhibition have also been shown to dampen tumorigenic 
inflammation, inhibit angiogenesis and migration, and improve antitumor activity of immune 
checkpoint inhibitors in vitro, in vivo and in clinical trials (75,106,462,463). 
In summary, our findings from Paper I open the door to new and distinct research avenues for 
PFKFB3 in DNA replication and repair, and provide the scientific community with a new class 
of potent and cell active PFKFB3 inhibitors with proven utility as investigational tools and 




2.4.2 MTHFD2 in nucleotide synthesis protein complexes 
 
While the role of one-carbon metabolism in nucleotide synthesis has been widely described in 
the literature (128,150,464), the specific contribution of MTHFD2 has been mostly implied 
from correlation studies based on general rearrangements of metabolic networks. Data from 
our lab and others strongly support a role for MTHFD2 locally at sites of nucleotide synthesis 
(200,211), including our findings in Papers III and IV, yet direct evidence of MTHFD2 
protein being found at these sites is still lacking.  
De novo purine and pyrimidine synthesis are long, multi-step processes requiring the concerted 
action of many different metabolic enzymes to catalyze individual biochemical reactions. To 
maximize the efficiency of these processes, enzymes involved in nucleotide synthesis have 
been described to form functional multi-protein complexes (215,465). Results from Paper III 
implicate MTHFD2 in de novo thymidylate synthesis, which together with observations of its 
nuclear localization and its association to chromatin upon DNA damage observed in Paper IV, 
suggest that it may be part of the nuclear dTMP synthesis complex, similar to other folate 
enzymes such as SHMT1, SHTM2 and MTHFD1 (215,217,275,466). Complementarily, 
preliminary data from our lab indicates that overexpression of MTHFD2 is enough to stimulate 
purine synthesis and that MTHFD2 enzymatic activity is required for maintenance and correct 
assembly of purinosomes (data not shown), in line with studies demonstrating the tight 
crosstalk between mitochondrial one-carbon metabolism and de novo purine synthesis (200). 
Subsequent insights from the MTHFD2i developed in Paper III show that their effects on cell 
viability can be potentiated by purine synthesis inhibitors (232), while they cannot be rescued 
by addition of purine intermediates 5-amino-4-imidazole-carboxamide (AICA)-riboside, 
adenine or adenosine (data not shown), suggesting their mechanism of action is mainly through 
alterations of de novo thymidylate synthesis. This is in line with siRNA data showing viability 
of MTHFD2-depeleted cells cannot be rescued by hypoxanthine. However, and in contrast to 
HL-60 cells, in SW620 and HCT-116 cells where thymidine rescue is partial, concomitant 
addition of hypoxanthine results in complete viability rescue (data not shown). This suggests 
that while targeting MTHFD2 can affect both purine and pyrimidine synthesis pathways, the 
extent to which they contribute to the MTHFD2i phenotype is likely cell and genetic context 
dependent.  
Part of the original thesis plan was to study the potential protein-protein interactions between 
MTHFD2 and other members of the thymidylate and purine biosynthesis complexes in the 
nucleus and mitochondria using subcellular fractionation, co-immunoprecipitation and 
isolation of proteins on nascent DNA (iPOND) (467) techniques, as well as efforts to purify 
and co-crystallize these complexes together with our structural biology collaborators. 
However, this remains to be investigated and constitutes an interesting line of research for the 




2.4.3 MTHFD2 in DNA repair mechanisms beyond HR 
 
In Paper IV, we described a new role for MTHFD2 in supporting HR repair of DSBs and 
proposed a potential application of MTHFD2 targeting to introduce HR deficiency specifically 
in cancer cells. We observed that MTHFD2 induction upon IR was affected by ATM inhibition, 
in line with the described function in HR, yet we also observed that this accumulation was 
abolished by inhibition of DNA-PK, an important regulator of NHEJ. Preliminary results using 
a DR-GFP assay variant to study DNA end-joining (EJ-GFP) revealed that siRNA depletion of 
MTHFD2 also significantly affected NHEJ repair potential of U2OS cells (data not shown). 
Taken together, this suggests an involvement of MTHFD2 prior to repair pathway choice. 
Since we established in Paper IV that MTHFD2 supports repair of DSBs downstream of ATM 
and DNA-PK kinase signaling but upstream of RPA and RAD51 recruitment, we suspected it 
could be related to incorrect or inefficient DNA resection. This would be in line with our model 
involving MTHFD2 in repair pathway choice, as DNA resection is a key determinant in the 
commitment to HR (468). Recently, MTHFD2 was found to mediate activation of DNA 
resection endonuclease EXO1 via CDK1 in mouse pluripotent stem cells (469). Both DDR and 
one-carbon metabolism pathways are highly conserved in mammals, implying the MTHFD2-
CDK1-EXO1 interaction may also be maintained in human cells, thereby explaining our 
observations. Moving forward with the MTHFD2 project, it will be important to (1) determine 
whether this mechanism translates in the human context, (2) further characterize the 
involvement of MTHFD2 in NHEJ repair, and (3) investigate its potential effects on alternative 
DNA repair pathways. 
 
2.4.4 Potential combination strategies for MTHFD2i 
 
To further validate the proposed mechanism of action of MTHFD2i presented in Paper III, we 
predicted and confirmed that combination of MTHFD2i and dUTPase inhibitors would 
potentiate deleterious misincorporation of uracil into replicating DNA and enhance cancer cell 
killing. Indeed, dUTPase seems to have a critical role in promoting the resistance and survival 
of cancer cells upon treatment with TS inhibitors such as 5-FU, 5-FUdR and raltitrexed 
(246,258,470). In clinical trials, dUTPase inhibitors such as TAS-114 have shown anticancer 
efficacy, however when combined with 5-FU result in increased levels of severe grade 3/4 
toxicity (471–473). These limiting adverse effects are likely the result of TS expression across 
healthy tissues, which presents an opportunity for inhibitors of the cancer-enriched MTHFD2 
to achieve a similar thymineless death phenotype specifically in tumor cells and sensitizing 
them, and not healthy cells, to dUTPase inhibition, effectively reducing severe toxicity. 
Likewise, in Paper III we tested the potential combination of MTHFD2i and inhibitors of the 
replication stress response, notably ATR. CHK1 and WEE1 inhibitors, to confirm the proposed 
role of MTHFD2 in supporting DNA replication. We demonstrated great synergistic potential 
between MTHFD2i and inhibitors of the ATR signaling cascade in inducing cancer cell killing, 
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with the ability to significantly sensitize MTHFD2i-resistant U2OS cells to treatment. 
Development of targeted DDR inhibitors suppressing ATR signaling has grown exponentially 
in recent years, demonstrating promising antitumor activity and combination potential in Phase 
I and Phase II clinical trials (240,241,300,301,314). Combination of potent ATR inhibitor VE-
822 with DNA damaging agent topotecan has shown great anticancer efficacy against advanced 
solid tumors in Phase I trials (474). Unfortunately, similar to dUTPase and 5-FU, the study also 
demonstrated increased levels of dose-limiting grade 3/4 hematological toxicities which 
followed the pattern of topotecan toxicity. Therapeutic restriction due to lack of cancer 
specificity by topotecan represents yet another instance where MTHFD2i could prove useful 
in potentiating the clinical efficacy of ATR inhibition with fewer side effects. 
Paper IV described the role of MTHFD2 in DSB repair, implying potential synergies for 
MTHFD2i with radiotherapy and PARP inhibitors. Early in vivo results for the MTHFD2i and 
talazoparib combination, while positive, were not striking. This could be due to the choice of a 
weaker MTHFD2i or a suboptimal AML model. It would be interesting to test the combination 
in HR proficient vs. deficient cells and optimize additional experimental parameters to evaluate 
the full potential of this promising combination therapy. Other studies targeting MTHFD2 in 
combination with radiotherapy also found a radiosensitization effect when combined with ROS 
inducing beta-lapachone (475). As observed by the near-complete rescue of MTHFD2i cancer 
cell killing by thymidine supplementation in Paper III, we conclude that this class of inhibitors 
acts mainly through their effects on DNA replication in AML cells. Nevertheless, MTHFD2i 
combination regimens in other tumor types such as breast, ovarian, colorectal and prostate 
cancers upon development of resistance to PARP inhibition may be worth evaluating. 
Additional studies have also explored the potential of combining MTHFD2 inhibition with 
secondary metabolic targets such as inhibition of SHMT1 to prevent rescue through cytosolic 
reversal of one-carbon directionality (181,384), and inhibition of de novo purine synthesis 
enzyme phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazole-
succinocarboxamide synthase (PAICS) (232). More recent observations have also suggested 
roles for MTHFD2 in conferring higher ROS tolerance upon cisplatin treatment (476), and in 
promoting tumorigenesis via PD-L1 expression and stabilization of MYC (477). Consequently, 
there is promising potential for MTHFD2i as sensitizers to platinum drugs and cancer 
immunotherapy which deserves further validation. Finally, CRISPR-Cas9 screens to find 
additional synthetic lethal interactions with MTHFD2i beyond the ones described above would 
be of particular interest.  
 
2.4.5 Folate transport and biomarkers to predict MTHFD2i response 
 
Among the biggest challenges in cancer drug development is finding out which patients are 
most likely to benefit from a given therapy. The success of recent targeted therapies has relied 
mainly on selecting patients by target gene expression levels or increased activity in associated 
pathways. Unfortunately, the same strategy has not proven as predictive for metabolic cancer 
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therapies (30). For example, DHFR and TS targets are present and overexpressed in virtually 
all cancers, yet the efficacy of antifolates and 5-FU across tumor types varies considerably. 
Similarly, we have found that while MTHFD2 is the most common overexpressed metabolic 
target in cancer, response to MTHFD2i is far from universal.    
In Paper III, in vitro pharmacological evaluation of MTHFD2i revealed the compounds had 
poor membrane permeability due to their highly polar hydrophilic structures, yet retained 
potent cell activity, suggesting compound uptake occurs via active transport similar to other 
folate-based metabolites and antifolate drugs.  
Besides the main folate carrier, RFC, two other main folate transport systems exist in cells: 
folate receptors (FRs) and the proton-coupled folate transporter (PCFT) (478–480). 
Additionally, mitochondrial folate trafficking is mediated by the mitochondrial folate 
transporter (MFT) (481). The differential regulation, expression and activity levels of these 
various carrier systems across tissues are important determinants of folate uptake, and together 
with FPGS, gamma-glutamyl hydrolase (GGH) and folate hydrolase 1 (FOLH1), modulate 
intracellular concentrations of folate molecules (160,162,482,483).  
Evaluation of our MTHFD2i and their structural features allowing or impeding 
polyglutamylation by FPGS revealed that the ratio between cellular and biochemical potency 
favored those compounds which could be polyglutamylated, in line with what is known about 
intracellular retention of folate derivatives. While we have confirmed TH9619 to be a substrate 
for FPGS, the extent to which the different folate transporters are involved in mediating 
TH9619 transport and efficacy remains to be determined. Structurally similar methotrexate and 
pemetrexed are mainly transported by RFC and PCFT (482), and so future efforts to investigate 
TH9619 transport mechanisms should consider these carriers first. Understanding the 
intracellular transport and subcellular distribution of MTHFD2i is key to isolate compartment-
specific contributions to their anticancer efficacy, to determine additional response-predictive 
factors, and to tackle potential resistance mechanisms. 
Factors involved in polyglutamylation may also predict response to MTHFD2i. FPGS and 
GGH, as master regulators of folate polyglutamylation and intracellular retention, are also 
predictors of treatment outcome upon antifolate and 5-FU therapy in gastric and lung cancer 
clinical trials (484,485). FOLH1, also known as prostate-specific membrane antigen (PSMA), 
has been used as a biomarker in prostate and breast cancer, with higher PSMA levels correlating 
with poor clinical outcome and increased relapse frequencies (486). These factors should also 
be considered in the selection of potentially MTHFD2i-sensitive tumors. 
Finally, given the high level of redundancy and plasticity within the one-carbon metabolic 
pathways, expression levels of other one-carbon metabolism enzymes may also influence 
response to MTHFD2i. In particular, cytosolic MTHFD1 and SHTM1 have been shown to 
mediate one-carbon metabolic flux reversal upon loss of MTHFD2 (181). Empirically, HL-60 
cells demonstrate the best response to our MTHFD2i among the cells tested thus far, and 
coincidentally also have display high levels of MTHFD2 expression together with low 
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MTHFD1 and SHMT1 protein levels (see Paper III). Constitutive KRAS activation and 
signaling has also been described to enhance the dependency on folate metabolism and predict 
response to MTHFD2i in vitro and in vivo (205,206,222).  
Altogether, the evidence shows that response to metabolic target inhibition, and in this case to 
MTHFD2i, is extremely complex. Above we have outlined perhaps the biggest determinants 
of MTHFD2i efficacy besides MTHFD2 expression, however future studies are needed to 
uncover additional mechanisms and genetic contexts arbitrating response to MTHFD2i. 
One major caveat of antifolate drug development is the lack of optimal pre-clinical models for 
drug evaluation. Murine models, which are the backbone of translational research, are poorly 
suited for demonstrating antifolate efficacy as their intrinsic levels of folate and nucleoside 
metabolites are orders of magnitude higher than those found in humans (487). These metabolic 
differences often mask any potential effects and complicate pre-clinical evaluation of 
antifolates. The workaround used in Paper III was to feed the mice low-folate chow for two 
weeks prior to study start and throughout the duration of the study, to reduce the animals’ folate 
and thymidine levels enough. However, prolonged folate deficiency in the mice can also lead 
to a wide range of toxicities and may confound the efficacy and safety profile of the candidate 
drugs. In lieu of established rodent pre-clinical models, new technological approaches such as 
ex vivo drug screening may hold the key to improve pre-clinical evaluation of MTHFD2i 
efficacy and safety (488). 
Despite a great number of recent discoveries, there is still a pressing need to improve our 
understanding of MTHFD enzymes, particularly in terms of designing new drugs targeting 
specific isozymes and associated molecular mechanisms. As for the future of MTHFD2i, we 
are currently working towards progressing suitable candidates into clinical development. Early 
in vivo characterization of TH9619 is promising, but further experiments are required to find 
alternative pre-clinical models and to optimize drug response prediction. Of immediate interest 
is the elucidation of MTHFD1 and MTHFD2 contributions to the anticancer effect of TH9619, 
which may have direct implications for response markers and selection of potentially sensitive 
cancers. Nevertheless, TH9619 represents a high quality MTHFD1/2 probe molecule that can 
continue to be used to uncover the complexities of established and non-canonical MTHFD 
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